



# LUND UNIVERSITY

## Mechanisms of survival and maintenance of Hematopoietic Stem Cells and Multipotent Progenitor Cells

Karlsson, Richard

2003

[Link to publication](#)

*Citation for published version (APA):*

Karlsson, R. (2003). *Mechanisms of survival and maintenance of Hematopoietic Stem Cells and Multipotent Progenitor Cells*. [Doctoral Thesis (compilation), Department of Translational Medicine]. Richard Karlsson Entr. 78, 3rd floor, U-MAS, S-205 02 Malmö, Sweden,.

*Total number of authors:*

1

### General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00



From the Department of Laboratory Medicine, Division of Molecular Medicine,  
Lund University, Sweden

**Molecular Mechanisms of Survival and Maintenance  
of Hematopoietic Stem Cells and Multipotent Progenitor Cells**

**Richard Karlsson**

With the approval of the Lund University Faculty of Medicine,  
this thesis will be defended on November 27, 2003, at 13:15,  
at the main lecture hall, Department of Pathology, entrance 78,  
University Hospital MAS, Malmö

Faculty opponent: Dr. Gunnar Nilsson, Uppsala University



Organization LUND UNIVERSITY  Department of Laboratory Medicine Division of Molecular Medicine University Hospital MAS	Document name DOCTORAL DISSERTATION	
Author(s) Richard Karlsson	Date of issue November 27th 2003	
	Sponsoring organization	
Title and subtitle Mechanisms of survival and maintenance of Hematopoietic Stem Cells and Multipotent Progenitor Cells		
Abstract <p>Hematopoietic stem cells and progenitor cells are maintained in the bone marrow microenvironment, where factors including soluble and membrane-bound cytokines influence the processes of self-renewal, proliferation and differentiation. Two nonredundant cytokines with effects on hematopoiesis, Kit Ligand (KL) and Flt3 Ligand (FL), signal via related tyrosine kinase receptors, c-kit and Flt3. In this thesis, we have studied which signaling pathways that are activated by these cytokines and are important for survival. We have shown that the serine-threonine kinase PKB (also known as Akt) is activated by both cytokines, but the upstream target PI-3 kinase is only necessary for the survival induced by KL and not FL. Also, KL could not prevent apoptosis in cells overexpressing a dominant negative form of PKB. The forkhead transcription factor FoxO3, which is phosphorylated and inactivated by PKB, was further shown to be of central significance for KL-mediated survival. The survival signals mediated by FL was shown to include antiapoptotic Bcl-2 family proteins. When overexpressed in progenitor cell lines, Bcl-2 was more effective in blocking apoptosis than PKB. Although both Bcl-2 and PKB could prevent a decrease in the mitochondrial membrane potential, Bcl-2 was superior with this respect. Some enhancement in survival was also seen when both proteins were overexpressed simultaneously. Finally, we studied the survival of bone marrow-derived multipotent hematopoietic progenitors in the presence of low levels of oxygen, hypoxia. We showed that survival was enhanced by hypoxia and improved the expansion of primitive colony forming cells.</p>		
Key words: Hematopoiesis, progenitor, cytokines, KL, c-kit, FL, Flt3, apoptosis, Bcl-2, Akt/PKB, forkhead, hypoxia.		
Classification system and/or index terms (if any):		
Supplementary bibliographical information:	Language English	
ISSN and key title:	ISBN 91-628-5827-0	
Recipient@notes	Number of pages 123	Price
	Security classification	

Distribution by (name and address) Richard Karlsson, Entr. 78, 3rd floor, U-MAS, S-205 02 Malmö, Sweden  
 I, the undersigned, being the copyright owner of the abstract of the above-mentioned dissertation, hereby grant to all reference sources permission to publish and disseminate the abstract of the above-mentioned dissertation.

Signature Richard Karlsson Date 2003-10-20

The Red Queen:

“You have to run faster than that  
to stay in the same place”

from Through the Looking Glass



## CONTENTS

<b>ABBREVIATIONS</b> .....	6
<b>LIST OF PAPERS</b> .....	8
<b>INTRODUCTION</b> .....	9
<b>BACKGROUND</b> .....	10
The hematopoietic stem cell .....	10
Embryonic origin of hematopoietic stem cells .....	11
Isolation of hematopoietic stem cells .....	11
Evaluation of hematopoietic stem cells .....	13
<b>REGULATION OF HEMATOPOIESIS</b> .....	14
Hematopoietic hierarchy .....	14
Hematopoietic cytokines and self-renewal .....	16
c-kit/KL and Flt3/FL .....	17
Bcl-2 family proteins and apoptosis .....	19
PI-3 kinase, Akt/PKB, and forkhead .....	21
Hypoxia and HIF .....	24
<b>PRESENT INVESTIGATION</b> .....	26
Comparison of induction of Bcl-2 family proteins by IL-3, KL and FL (Paper I) .....	26
Activation of Akt/PKB and inactivation of forkhead by KL (Paper II) .....	27
Antiapoptotic effects of Bcl-2 and Akt/PKB in combination with KL (Paper III) .....	28
Antiapoptotic effects of hypoxia in combination with KL (Paper IV) .....	29
<b>DISCUSSION</b> .....	30
<b>FUTURE STUDIES</b> .....	33
<b>SAMMANFATTNING</b> .....	36
<b>ACKNOWLEDGEMENTS</b> .....	38
<b>REFERENCES</b> .....	39
<b>PAPER I</b> .....	63
<b>PAPER II</b> .....	75
<b>PAPER III</b> .....	85
<b>PAPER IV</b> .....	107

## **ABBREVIATIONS**

AGM	dorsal aorta, gonads and mesonephros
ASK	apoptosis signal-regulating kinase
ATF	activating transcription factor
AML	acute myeloid leukemia
ANT	adenine nucleotide translocater
Bax	Bcl-2 associated protein x
Bcl	B cell lymphoma
BCRP	breast cancer resistance protein
BH	Bcl-2 homology
BFU	burst forming unit
BM	bone marrow
CD	cluster designation
CFC	colony forming cell
CFU	colony forming unit
CLP	common lymphoid progenitor
CMP	common myeloid progenitor
CSF	colony stimulating factor
E	erythrocyte
ED	embryonic day
ELTC-IC	extended long-term culture-initiating cell
epo	erythropoietin
FACS	fluorescence activated cell sorter
FL	Flt3 ligand
FRAP	FKBP-rapamycin-associated protein
G	granulocyte
GLUT	glucose transporter
GMP	granulocyte/monocyte progenitor
GSK	glycogen synthase kinase
HIF	hypoxia-inducible factor
HPP	high proliferative potential
HSC	hematopoietic stem cell
IAP	inhibitor of apoptosis
IL	interleukin



---

JNK	c-Jun N-terminal kinase
KL	c-kit ligand
LIF	leukemia inhibitory factor
LT-HSC	long-term HSC
LTC-IC	long-term culture initiating cell
M	macrophage
Mcl	myeloid cell leukemia
Meg	megakaryocyte
MEP	megakaryocytic/erythroid progenitor
MPP	multipotent progenitor
mTOR	mammalian target of rapamycin
NK	natural killer
PAS	para-aortic splanchnopleura
PDK	phosphatidylinositol-dependent kinase
Pgp	P-glycoprotein
PH	pleckstrin homology
PI	phosphatidylinositol
PKB	protein kinase B
PTEN	phosphatase and tensin homologue deleted on chromosome 10
PTP	permeability transition pore
S	spleen
SCID	severe combined immune deficiency
SCL	stem cell leukemia
SH	src homology
SP	side population
ST-HSC	short-term HSC
TNF	tumor necrosis factor
Tpo	thrombopoietin
VDAC	voltage-dependent anion channel
VEGF	vascular endothelial growth factor
wt	wild type

## LIST OF PAPERS

This thesis is based on the following papers, which are referred to in the text by their respective roman numerals.

- I      **Phosphatidylinositol 3-kinase is essential for Kit ligand-mediated survival, whereas interleukin-3 and Flt3 ligand induce expression of antiapoptotic *Bcl-2* family genes**  
Richard Karlsson, Maria Engström, Maria Jönsson, Peter Karlberg, Cornelis J. H. Pronk, Johan Richter, and Jan-Ingvar Jönsson  
*Journal of Leukocyte Biology* 74(5), 2003
  
- II     **Inactivation of the forkhead transcription factor FoxO3 is essential for PKB-mediated survival of hematopoietic progenitor cells by Kit ligand**  
Maria Engström, Richard Karlsson, and Jan-Ingvar Jönsson  
*Experimental Hematology* 31(4):316-323, 2003
  
- III    **Akt/PKB promotes antiapoptotic signaling in hematopoietic progenitor cells but does not account for Kit ligand-mediated survival in combination with Bcl-2**  
Richard Karlsson, Maria Engström, Maria Jönsson, Camilla Persson, and Jan-Ingvar Jönsson  
*Manuscript*
  
- IV    **Enhanced self-renewal and survival of primitive hematopoietic progenitor cells by early acting cytokines in combination with hypoxia**  
Richard Karlsson, Håkan Axelson, and Jan-Ingvar Jönsson  
*Manuscript*

Reprints were made with permission from the publishers.

© 2003 Society for Leukocyte Biology

© 2003 International Society for Experimental Hematology

## INTRODUCTION

Homeostasis, the maintenance of blood cells, is maintained throughout life by a rare cell type residing primarily in the bone marrow (BM), where it makes up less than 1 in  $10^4$  to  $10^5$  cells [1]. This cell type, the hematopoietic stem cell (HSC), gives rise to all blood cell progenitors through differentiation, but at the same time replenishes the pool of undifferentiated cells. While self-renewal and differentiation of HSCs and progenitor cells appear to be mostly stochastic processes within the cells, survival and proliferation are regulated by external factors [2,3]. Part of this regulation is due to a complex interaction between soluble and membrane-bound stimulatory and inhibitory cytokines and their corresponding receptors. Although a number of cytokines have extensive effects on HSCs and progenitor cells *in vitro* or *in vivo*, c-kit ligand (KL; also known as stem cell factor or mast cell growth factor) and Flt3 ligand (FL), appear to have unique and nonredundant activities on these cells [4].

The circumstances that regulate HSCs self-renewal and maintenance are not clear, but the HSC niche in the BM provides the environment to sustain long-term hematopoiesis [5,6]. Apart from cytokines, the extracellular matrix in the BM can present adhesion molecules, and it is thought that the interaction between signals induced by cytokines and adhesion molecules are important for hematopoiesis [7-9]. The BM is generally seen as well perfused with blood, but areas of lower oxygen levels, hypoxia, may also have a role in determining stem cell differentiation [10]. Indeed, several reports have shown that marrow repopulating ability is maintained by incubation in hypoxia [11-14].

The factors regulating the HSCs and progenitor cells induce survival signals that still are not elucidated. The B cell lymphoma (Bcl)-2 family of proteins (reviewed in [15]) and protein kinase B (PKB; also known as Akt, reviewed in [16]) have been inferred with these signals. However, further knowledge on the mechanisms that support survival of HSC and progenitor cells are needed. Therefore, in this thesis, we have investigated the relationships between KL and FL signaling and Bcl-2 and PKB. Also, the effects of hypoxia with early acting cytokines including KL on survival and self-renewal was studied.

## BACKGROUND

### The hematopoietic stem cell

The turnover of cells of the hematopoietic system in an individual weighing 70 kg are close to 1 trillion ( $10^{12}$ ) per day, including 200 billion erythrocytes and 70 billion neutrophilic leukocytes [3]. The cells of the hematopoietic system originate from a common progenitor cell, the HSC, which is able to produce a steady level of erythroid, lymphoid and myeloid cells throughout a lifetime [17,18].

The HSC is defined by several characteristics. First, the HSC is the only cell that is capable of long-term reconstitution of the hematopoietic system of a BM ablated/lethally irradiated recipient. By limiting dilution it has been shown that only a few cells are needed for this, which indicates the high proliferative potential of HSCs. Reconstitution of hematopoiesis can be further transferred into secondary and tertiary hosts. Second, in order not to exhaust the pool of HSCs, they must have the capacity to self-renew (i.e. to divide and produce daughter cells, which retain the properties of the original cell). Third, the HSC has the capacity to undergo differentiation and is able to form all different cell types in the hematopoietic system [19-23].

HSCs can be maintained in a non-cycling state (quiescence) for long periods of time. From this phase outside the cell cycle ( $G_0/G_1$ ), a few HSCs at a given time re-enter the cell cycle and contribute to maintain the steady state of hematopoiesis. It has been calculated that approximately 8% of HSC asynchronously enter the cell cycle per day. Although approximately 75% of HSC are quiescent in  $G_0$  at any one time, all HSCs are recruited into cycle regularly such that 99% of HSC divide on average every second month [24,25].

In recent years, the question whether stem cells are restricted to specific tissues or have the potential to differentiate into cell types normally not associated with the lineage they were derived from, has been challenged. This process of transdifferentiation (plasticity), has been shown in experiments with HSCs, where these cells could regenerate functional hepatocytes [26,27]. Neuronal stem cells have also been found to produce a variety of blood cell types, including myeloid and lymphoid cells as well as early hematopoietic cells. However, these and other transdifferentiation events are low in number and could be due to fusion between the different cell types involved [28-31].

**Embryonic origin of hematopoietic stem cells**

In the mouse embryo, there are three sites where hematopoiesis takes place; the yolk sac, the PAS-AGM (para-aortic splanchnopleura/dorsal aorta, gonads and mesonephros) region, and the fetal liver [32,33]. Hematopoiesis originally occurs by embryonic day (ED)7-7.5 in the yolk sac blood islands. These erythrocytes are primitive and can only form erythroid and myeloid progeny and lack the potential to produce lymphoid cells. Multipotent progenitors with erythroid/myeloid and lymphoid potential are generated first in the PAS region, that later develops into the AGM region. These cells appear to colonize the yolk sac beginning at ED8.5, when the circulation between these tissues is established. The first HSCs capable of full long-term, multilineage engraftment of lethally irradiated adult recipients are found in the AGM region at beginning of ED10. These cells are generated only in the AGM region and subsequently appear to colonize the fetal liver, which is the primary site for hematopoiesis during embryogenesis [34-36]. Shortly prior to birth, the BM becomes the primary site for hematopoietic generation. The BM is subsequently the primary organ where the multipotent HSCs can be found in normal adults [37].

In embryonic hematopoiesis, there is a key role for the basic helix-loop-helix transcription factor stem cell leukemia (SCL)/Tal. Expression of SCL/Tal is detected in embryonic and extraembryonic mesoderm at ED7.5, in blood islands of the yolk sac by ED8.5, and thereafter in adult hematopoietic tissues. Embryos lacking SCL/Tal lack embryonic red cells and die between ED9-10.5 due to anemia, and enforced expression of SCL/Tal can induce a stimulatory effect at the level of erythroid and megakaryocytic progenitor cells, while exerting a selective proliferative action on downstream erythropoiesis [38-40]. An early role for SCL/Tal in hematopoiesis is also suggested by the immature phenotype of leukemic cells seen in humans with deregulated SCL/Tal expression [41]. Interestingly, SCL/Tal is required for c-kit expression in hematopoietic cells [42,43].

**Isolation of hematopoietic stem cells**

The most common sources of BM in mice are the femurs (thigh-bones) and tibiae (shin-bones). In adult humans, the BM is the primary reservoir of HSCs used for transplantations. HSCs from peripheral blood are commonly used for autologous or allogeneic transplantation following high-dose chemotherapy. The introduction of hematopoietic growth factors such as granulocyte-colony stimulating factor (G-CSF) has greatly enhanced the mobilization of HSCs from the BM, although the mechanism

of HSC mobilization is not yet clarified [44,45]. KL and FL can also induce recruitment of BM cells to the circulation, although this is not used clinically [46-49]. Umbilical cord blood is also a rich source of HSCs, since the stem cells in the fetus home to the BM via the blood [50].

Two inventions facilitated the technology of purification of HSCs; the advent of monoclonal antibodies and the development of the fluorescence activated cell sorter (FACS) [51]. It has been found that HSCs lack expression of many antigens present on mature and lineage committed blood cells, including cluster designation (CD) 3 (lymphocytes), B220 (murine B lymphocytes), CD19 (murine and human B lymphocytes), CD4 and CD8 (T lymphocytes), NK1.1 (natural killer (NK) cells), Mac-1/Gr-1 (myeloid cells), and Ter119 (murine erythroid cells). Murine HSCs have been shown to have at most a low expression of CD34 and to be expressing CD38 [52,53]. Contrary, human HSCs have been indicated to express CD34 and lack the expression of CD38 [54,55]. However, it was demonstrated that the CD34<sup>-</sup> fraction of normal human BM contains cells capable of long-term engraftment and which can differentiate into CD34<sup>+</sup> progenitors [56]. In agreement with the finding that HSCs are critically regulated by KL, c-kit is expressed on these cells [57]. Other markers, such as Sca-1 and Thy-1 are also used when isolating HSCs [26,58], although these antigens are mouse strain specific and cannot be used in all cases [59]. In the murine system, transplantation of single BM cells sorted as lineage negative, Sca-1 positive, c-kit positive and CD34 negative/low can reconstitute hematopoiesis for a lifetime [52].

Other strategies, including metabolic states, cell size and density gradients, can be used for the enrichment of HSCs. HSCs were early found to be more or less resistant to a number of cytostatic drugs, which exercise their effects primarily when DNA duplication is performed, and it was hypothesized that HSCs were mostly quiescent. In accordance with this, most HSCs in steady state can be found in the G<sub>0</sub>/G<sub>1</sub> of the cell cycle [25,60]. Moreover, HSCs have been found to be able to exclude certain compounds, and by use of the dyes Hoechst 33342 and Rhodamine 123, HSCs can be isolated [24]. These cells have been denoted the side population (SP), and extensive research is currently investigating the properties of these cells. It was initially believed that the multidrug resistance protein P-glycoprotein (Pgp) was responsible for this efflux, and Pgp was later found to be a marker for hematopoietic progenitor cells [61-63]. Transduction of murine BM cells with Pgp enabled *ex vivo* stem cell expansion, although they caused a myeloproliferative syndrome, and enforced Pgp pump function in murine BM cells

resulted in expansion of side population stem cells *in vitro* and repopulating cells *in vivo* [64,65]. These results indicate that Pgp could be involved in hematopoiesis, perhaps by influencing cell cycle regulation or by extrusion of differentiating compounds, since down-regulating multidrug resistance triggers proliferation of noncycling hematopoietic progenitors, and Pgp has been shown to have affinity for several hormones, among them retinoic acid [66-68]. Recently, breast cancer resistance protein (BCRP; also known as ABCG2), a multidrug resistance transporter closely related to Pgp, was also found to be overexpressed in HSCs [69]. This pump has been found to be responsible for the efflux of Hoechst 33342 and is a new putative marker for HSCs [70].

### **Evaluation of hematopoietic stem cells**

The best way to assess a HSC is its ability to reconstitute the hematopoiesis into a BM ablated recipient. For obvious reasons, this is not achievable with humans, although artificial systems exist (e.g., immuno-compromised mice or the *in utero* transfer into sheep fetuses) [56,71,72]. In the early 60s, the colony forming unit-spleen (CFU-S) assay was developed, where transplanted cells formed characteristic colonies on the spleens of lethally irradiated recipient mice [73,74]. Cells from these colonies were shown to be serial-transplantable, indicating self-renewal, but it has later been shown that these cells were already committed to the myeloid compartment, and thus the CFU-S assay is currently not considered to be an assay for HSCs [75].

In the mid 80s, a method was developed that used random chromosomal integration sites of retrovirus vectors as unique clonal markers to analyze cell lineage relationships within the hematopoietic stem cell hierarchy. Anemic mutant mice were reconstituted with infected BM and further analysis indicated insertion into primitive pluripotent stem cells capable of producing both myeloid and lymphoid progeny, as well as into more committed stem cells apparently restricted to either the myeloid or lymphoid lineages [20,22,76,77]. In all, these experiments proved that there indeed exists a cell in the BM that has, at the single cell level, the potential to both self-renew, form multilineage offspring and is able to functionally restore hematopoiesis.

By use of a stroma feeder layer that imitates the BM environment for the HSCs, an assay has been developed, the long-term culture initiating cell (LTC-IC) assay, and its modification, extended LTC-IC (ELTC-IC) assay [78-80]. The preformed layer of BM stromal cells is imagined to produce growth factors and to provide cell-to-cell contact with adhesion molecules and membrane-bound growth factors. Following 5-8 weeks

in culture, the cells are subsequently evaluated for their potential to form colonies in semisolid media, such as methylcellulose or agar as a response to cytokine stimulation. It is nowadays modified to evaluate both myeloid and lymphoid progenitors, including natural killer (NK) cells [50].

There are also assays for evaluating hematopoietic progenitor cells without any supporting cells. After *in vitro* incubation with cytokines the cells are seeded in semisolid media, and since the cells are immobilized, the different cell types from one colony represent the offspring from one original progenitor cell. Multipotent progenitor cells can thus give rise to multi-lineage colonies (e.g., colony forming unit-granulocytes, erythroids, macrophages and megakaryocytes, CFU-GEMM; colony forming unit-mix, CFU-mix; pre-colony forming cells multilineage, pre-CFC<sub>multi</sub>). One type of multi-lineage colony, the high proliferative potential colony forming cells (HPP-CFC), actually give rise to colonies that can be seen with the naked eye. More differentiated cells give rise to colonies with dual lineages, like granulocytes and macrophages (CFU-GM), and unipotent progenitors will give rise to colonies containing macrophages (CFU-M), granulocytes (CFU-G), megakaryocytes (CFU-Meg), and the burst forming unit-erythrocytes (BFU-E) [71,81-83].

## **REGULATION OF HEMATOPOIESIS**


### **Hematopoietic hierarchy**

The HSC is multipotent and is thus able to develop into the eight different hematopoietic lineages [3]. The exact mechanisms that underlie and direct these processes are still to a large degree unknown. However, due to recent years advances in cellular isolation and characterization techniques, a fairly descriptive picture of the earliest differentiation processes have evolved [84]. HSC can be divided into a long-term subset (LT-HSC), capable of indefinite self-renewal, as well as a short-term subset (ST-HSC) that self-renews for a defined interval. Each stage of differentiation of multipotent steps involves functionally irreversible maturation steps. The lineage of multipotent cells is thus LT-HSC that differentiates to ST-HSC, which in its turn differentiates to multipotent progenitors (MPP), that can give rise to the entire hematopoietic system, but has lost its capacity to self-renew [85]. Included in the progeny of mouse HSCs are two kinds of oligolineage-restricted cells: common lymphoid progenitors (CLPs), which at a clonal level are restricted to give rise to T lymphocytes, B lymphocytes,



and NK cells [86], and common myeloid progenitors (CMPs), which are progenitors for the myeloerythroid lineages. CMPs give rise to granulocyte/monocyte progenitors (GMPs) and megakaryocytic/erythroid progenitors (MEPs) [87]. All these populations (LT-HSCs, ST-HSCs, MPPs, CLPs, CMPs, GMPs, and MEPs) are separable as pure populations using cell surface markers (*Figure 1*, adapted from [84]).

How the differentiation process is controlled is not fully understood, and it is not clarified whether cell division is a prerequisite for differentiation to occur, or whether alterations in the genetic control can occur in a cell at cell cycle rest. The most immature lymphoid-committed progenitors (CLPs), have been shown to maintain a latent granulocyte/macrophage differentiation potential that can be initiated by signals emanating from interleukin-2 (IL-2) or granulocyte/macrophage- (GM-) CSF receptors. It was concluded that cytokine signaling can regulate cell fate decisions, and thus a critical step in lymphoid commitment is down-regulation of cytokine receptors that drive myeloid cell development. [88,89].



**Figure 1:** *The hematopoietic tree.*

### **Hematopoietic cytokines and self-renewal**

The hematopoietic cytokines have been suggested to regulate proliferation, survival, differentiation and cell activation. Cytokines mostly act on the auto- and paracrin level during hematopoiesis, which can lead to high concentrations locally, and regulation of cytokines is exerted by rapid degradation both on the mRNA and on the protein level [90]. That cytokines regulate differentiation is debated, and two models have been proposed. According to a *stochastic model*, the choice of lineage is decided intrinsically, independently of cytokines, and by chance. The role of cytokines would be to regulate proliferation and survival, and not for commitment, and thus select for cells that are responsive to the cytokine [91]. Suppression of programmed cell death (apoptosis) allowed differentiation of the multipotent hematopoietic cell line FDCP-mix in the absence of added growth factors, thus supporting the hypothesis that differentiation is intrinsically determined and that the role of the hematopoietic growth factors is enabling rather than inductive [92]. Also, insertion of the erythropoietin (epo) or macrophage (M)-CSF receptor into multipotent precursors, did not stimulate erythroid or macrophage colony formation, respectively, but increased proliferation of all progenitors [93].

However, an *instructive model* exists, that suggests that cytokines can induce differentiation. In support of this, studies have shown that a mutant form of G-CSF receptor is unable to conduct signals for differentiation, though it is still capable to relay signals for proliferation [3,94,95]. Both models may be correct in that they could act at different levels of hematopoiesis. The intrinsic factors controlling differentiation and commitment, whether controlled by cytokine signaling or by chance, are specific combinations of transcription factors. The transcription factors are often activated in positive autoregulatory loops, which can explain the irreversible differentiation processes found in hematopoiesis. Two important transcription factors for the maintenance of LT-HSCs are SCL/Tal, mentioned above as important in the embryonic development of hematopoiesis, and Lmo2, which has been shown to be able to physically interact with SCL/Tal, and thus regulate transcription [96,97].

Most cytokine receptors consist of two or three subunits, of which one is cytokine specific and binds the ligand, while another subunit transmits the intracellular signal. The receptor subunit mediating signal transduction is often shared by different receptors. For example, the receptors for IL-3, IL-5 and GM-CSF have a common signal transducing  $\beta$ -chain [98], and the family of cytokines signaling through the common receptor subunit gp130 comprises of IL-6, IL-11, leukemia inhibitory factor (LIF),

oncostatin M, ciliary neurotrophic factor and cardiotrophin-1 [99]. This could explain that, although the receptors have affinity for different cytokines, there is a redundancy between some of the hematopoietic cytokines. Also, this could explain the similarity of the effects from different cytokines, like the size of a colony formed after the addition of certain cytokines.

In order not to empty the stem cell pool, the HSCs have the capacity for self-renewal [3]. Upon cycling, HSCs may undergo symmetric division (i.e. either self-renewal or commitment to differentiation of the progeny) or asymmetric divisions (i.e. generation of a self-replicated and a differentiated cell). In the embryonic mice, an expansion of cells with LT-HSC activity can be seen in the AGM region after ED10 [36]. Although extensive amplification of LT-HSC numbers can be observed in recipients of adult LT-HSC transplants [52], attempts to enhance normal LT-HSCs *in vitro* have generally been without any success. However, when adult mouse BM cells were incubated for 10 days in serum-free medium with IL-11, FL and KL, there was a 3-fold increase of cells able to reconstitute the lymphoid and myeloid systems of recipient mice [100].

Other signals than cytokines, such as adhesion factors and ligands expressed in the surroundings of the HSC pool in the BM, could also be important for HSC self-renewal. Pluripotent HSCs are immortalized by constitutive Notch1 signaling, which could be a candidate mechanism for LT-HSC self-renewal [101]. It has also been shown that the Wnt signaling pathway has an important role in self-renewal, and that activation of Wnt signaling in HSCs induces increased expression of Notch, and also HoxB4, which has been implicated in self-renewal of HSCs [102-104]. Telomerase seems also to be important for HSC self-renewal, since telomerase activity has been found in HSCs, and long-term self-renewal of HSCs is compromised upon telomere loss. Unlike tumor cells, HSCs are not immortal and show decreasing telomere length with increasing age. Thus, telomerase may regulate self-renewal capacity by reducing the rate at which telomeres shorten [105,106].

### **c-kit/KL and Flt3/FL**

Absence of KL (the Steel mutation), or the cell surface receptor c-kit (the White mutation), results in death *in utero* or in the perinatal period with severe macrocytic anemia [107]. The gene corresponding to *c-kit* was cloned in the late 80s [108,109], and its ligand a few years later [110-116]. Mutations at either of these loci resulted in very similar phenotypes characterized by alterations of coat color (“white spotting”), anemia and lack of mast cells in the tissues, suggesting that the genes involved were important

for hematopoiesis and melanogenesis (reviewed by [4]). By use of reconstitution assays, it has been shown that LT-HSCs express c-kit [57], and progenitor cells for the lymphoid and myeloid compartments express c-kit as well [86,87]. Studies have indicated that c-kit is expressed at low levels on LT-HSCs, increases in density to reach a peak at the progenitor level, and then decreases with terminal maturation with the exception of basophiles/mast cells, who express high levels of c-kit [4]. That KL is important for the hematopoiesis has been shown in several studies, and it is interesting to note that it was the only cytokine, out of several studied, that was able to support *in vitro* proliferation and recruitment of HSCs by preventing apoptosis [117].

KL exists in both soluble and membrane-bound forms as a result of differential splicing and proteolytic cleavage. It has been shown that a more sustained signaling is mediated by membrane associated KL, and the phenotype of *Sl/Sl<sup>d</sup>* mice, which produce only soluble KL, have anemia, pigmentation defects and lack tissue mast cells [46]. KL has also been shown to promote the survival of HSCs and progenitor cells in the absence of cell division [118] and enhances hematopoiesis by synergistic interactions with early acting cytokines [83,119-121]. However, differentiation into B cells can occur in the absence of c-kit [122].

The Flt3 receptor has strong sequence similarities with other members of the class III tyrosine kinase receptors family, which includes c-kit, and it was cloned in 1991 [123-125]. Using the receptor as bait, the corresponding ligand was cloned some years later [126,127]. Flt3 has been reported to have a fairly limited expression pattern confined to candidate HSCs and more committed progenitors [4]. Mice lacking FL or its receptor Flt3 have deficiencies in hematopoiesis [128,129], but recent studies indicate that the effects are mostly on the lymphoid compartment [130]. It has recently been shown that LT-HSCs do not seem to express Flt3 receptor [131,132], and cell cycle analysis shows that a large number of cells expressing low levels of Flt3 receptor are in the G<sub>0</sub> phase of the cell cycle, whereas cells with high expression are predominantly in G<sub>1</sub>. This is in accordance with the observation that FL can induce proliferation of hematopoietic progenitor cells [133].

Endothelial cells (EC) express a membrane-bound form of FL and produce large amounts of soluble FL, which are derived from the membrane-bound FL by proteolytic release. BM microvascular EC also produce FL, suggesting that EC are an important source of FL in the BM [134,135]. FL has been shown to stimulate the expansion of primitive murine BM progenitor cells *in vitro* and to have synergistic interactions

with hematopoietic growth factors [127,136-140]. FL also promotes the survival of primitive hematopoietic progenitor cells with B lymphoid as well as myeloid potential [141,142].

Although similar in structure, c-kit and Flt3 seem to convey different functions in the hematopoietic system [143]. A major difference between FL and KL is that FL has no growth promoting effects on progenitors committed to the erythrocyte, megakaryocyte, eosinophil, or mast cell lineages [137,144]. Instead, FL interacts with IL-7 to promote B-cell commitment and differentiation from uncommitted BM progenitor cells [145]. Though not studied in detail for the Flt3 receptor, c-kit and Flt3 seem to activate similar transduction components, which include the Src family members, the JAK/STAT pathway, the Ras-Raf-MAP kinase cascade and phosphatidylinositol-3 (PI-3) kinase [146]. KL and FL have also shown synergistic effects in supporting [79] and expanding [100] LT-HSCs and dendritic progenitor cells [147].

### **Bcl-2 family proteins and apoptosis**

In order to maintain a steady state of hematopoiesis, HSCs can either self-renew or commit to differentiation. In the case of an overcapacity, apoptosis can also be induced. One reason why the culturing of HSCs fails, is that the cells undergo apoptosis, but blockage of apoptosis alone does not permit successful culture. Simply blocking apoptosis, for example by overexpressing the Bcl-2 protooncogene in the absence of the correct stimuli, leads to differentiation of the cells [92,148].

Bcl-2 was initially identified as a cellular gene located at the site of a frequent t(14; 18) chromosomal translocation in follicular B cell lymphomas [149,150] and systemic overexpression of Bcl-2 in the hematopoietic system protects from apoptosis [151-153]. In the adult, Bcl-2 is expressed in BM progenitor cells representing all lineages, suggesting a role in the survival of these immature cells [154]. Bcl-2<sup>-/-</sup> mice develop normally, but later exhibit marked lymphoid apoptosis [155]. Crosses of knockout mice revealed that the proapoptotic Bcl-2-associated protein x (Bax) is responsible for the death of lymphoid cells in Bcl-2<sup>-/-</sup> mice [156].

The Bcl-2 family proteins are divided into three groups depending on their functions. The *Bcl-2-like survival factors* (e.g., Bcl-2, Bcl-x<sub>L</sub>, Mcl-1 and Bfl-1/A1) contain three to four so-called Bcl-2 homology domains (BH1-BH4), which are absolutely required for their survival functions. *Bax-like death factors* (e.g., Bax, Bak and Bok) lack the N-terminal BH4 domain, although this is probably not the cause for their death-inducing

capacity. Finally, the *BH-3-only death factors* (e.g., Bim, Bad and Bid), which are so-called because they share with each other, and with the other members of the Bcl-2 family of proteins, only the BH3 domain (reviewed in [15]).

In short, most of the pro- or antiapoptotic effects are seen when the Bcl-2 family proteins are integrated into membranes, especially the mitochondria [157]. It is believed that the Bcl-2-like survival factors only repress the function of the Bax-like death factors [158]. Alternatively, the Bcl-2-like survival factors and the Bax-like death factors either form pores in the mitochondria, thus regulating the function of the organelle, or stabilize or perturb a pre-existing channel (the “permeability transition pore”; PTP), that forms across sites of contact between the inner and outer membranes of the mitochondria, through which adenine nucleotides and other small molecules traffic [159]. The core components of this channel include the voltage-dependent anion channel (VDAC) in the outer membrane, adenine nucleotide translocater (ANT) in the inner one, and cyclophilin D in the matrix [160].

In any case, the BH3-only death factors are thought to regulate the function of the other two groups, either by inhibiting the antiapoptotic Bcl-2-like survival factors, or by enhancing the function of the proapoptotic Bax-like death factors. If the balance of the pro- and antiapoptotic Bcl-2 family proteins favors apoptosis, cytochrome c, which is a part of the electron transport chain, is released into the cytosol. There it forms an “apoptosome” together with Apaf-1 and procaspase-9, which is cleaved to form the activated caspase-9. Caspase-9 in its turn cleaves caspase-3 and other caspases, executing the programmed cell death (reviewed in [161,162]).

As mentioned above, Bcl-2 and Bax have been shown to have a role in the survival of hematopoietic cells. There seems to be a redundant function of Bax and Bak, and individual Bax and Bak knock-out mice have remarkably little immune phenotype. Bax deficient mice have mild hyperplasia and Bak-deficient mice have no discernable phenotype at all [163]. In contrast, Bax<sup>-/-</sup>/Bak<sup>-/-</sup> mice have increased hematopoietic progenitor cells in the BM and white blood cells in the blood. The spleens and lymph nodes are also up to 30-fold enlarged [164]. The myeloid cell leukemia-1 gene (Mcl-1) was discovered because its expression increased early in the differentiation of a myeloid leukemia cell line [165]. Mcl-1 interacts with Bax in hematopoietic FDC-P1 cells and can prolong cell viability [166]. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage [167]. Bax and Bak have been shown to accelerate the opening of VDAC, allowing

cytochrome c to pass through, whereas the antiapoptotic protein Bcl-x<sub>L</sub> closes VDAC by binding to it directly [168]. Bcl-x<sub>L</sub> has been reported to be expressed in primitive hematopoietic progenitors [169], and null mutants die during embryogenesis with severe hematopoietic deficiencies [161,170,171].

Hematopoietic cytokines have been shown to regulate Bcl-2 family members. A1 is necessary for cytokine-dependant neutrophil survival [172,173], whereas Hrk has been shown to be induced in hematopoietic progenitors after growth factor deprivation [174]. FL has been shown to prevent upregulation of Bax [175], and KL has been shown to upregulate Bcl-2 in NK cells [176], and both Bcl-2 and Bcl-x<sub>L</sub> in erythroid progenitors [177,178]. Also, Mcl-1 has been shown to be a target of KL and interleukin-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/PKB pathways [179].

Another, partly mitochondria-independent apoptotic pathway has also been inferred with hematopoiesis; the activation of the death-inducing Fas and tumor necrosis factor (TNF) receptors by their respective ligand. This pathway has been shown to be functional in hematopoietic progenitor cells [180-182], fetal HSCs [183] and LT-HSCs [184,185]. Activation of these receptors activates caspase-8, which in its turn activates caspase-3 without the involvement of the mitochondria. However, caspase-8 is also able to cleave cytosolic Bid, generating a smaller fragment that translocates to the mitochondria and enhances the release of cytochrome c [157].

### **PI-3 kinase, Akt/PKB, and forkhead**

PI-3 kinase is a heterodimer consisting of two subunits, catalytic and regulatory, with molecular weights of 110 kD (p110) and 85 kD (p85), respectively. The regulatory p85 subunit consists of several motifs implicated in protein-protein interaction, which include two src homology 2 (SH2) domains, an SH3 domain, a proline-rich domain, and the inter SH2-sequence which is responsible for binding to p110 [186,187]. KL induces the association of p85 with c-kit through the SH2 domains and thus localizes p110 together with potential substrates at the plasma membrane, where it produces 3'-phosphorylated phospholipids including the PI-3,4-P<sub>2</sub> and PI-3,4,5-P<sub>3</sub> [188-190].

Knockout studies have shown an important role of PI-3 kinase in hematopoiesis, including both lymphoid and myeloid cells [191-193]. Both PI-3,4-P<sub>2</sub> and PI-3,4,5-P<sub>3</sub> bind with high affinity to the pleckstrin homology (PH) domain of several proteins, including PKB and PI-dependent kinase 1 (PDK1). In response to KL, PI-3,4-P<sub>2</sub> and PI-3,4,5-P<sub>3</sub> recruits PKB to the plasma membrane, where it can be phosphorylated and




activated by PDK1, which by itself is PI-activated [194]. PI-3,4-P<sub>2</sub> and PI-3,4,5-P<sub>3</sub> can be dephosphorylated on the 3' of the inositol ring by PTEN (phosphatase and tensin homologue deleted on chromosome 10), thus inhibiting PKB activity [195,196].

The oncogenic PKB was originally cloned from a T cell lymphoma where it was truncated and fused to the viral sequence [197]. Mutations of c-kit activating the PI-3 kinase/PKB pathway have been implicated in a variety of malignancies, including acute myeloid leukemia (AML) [198]. Active PKB has been found to phosphorylate several substrates including Bad [199-201], IKK [202], glycogen synthase kinase-3 (GSK-3) [203], proteins involved in nitric oxide synthesis [204,205], caspase-9 [206], p70S6K [207] and forkhead transcription factors [208-210]. Although the antiapoptotic activity of PKB is well known, it also regulates other aspects of cellular functions, including migration, protein synthesis, and glycolysis [211].

PKB controls several processes involved in metabolism, which include effects on the activity of GSK-3 and p70S6K, the translocation of the glucose transporter (GLUT) 4 to the plasma membrane, the induction of GLUT 1 synthesis and the activation of hexokinase and other enzymes involved in glucose metabolism [212-218]. Although many of these processes are cell-type specific, PKB may generally regulate aspects of metabolic homeostasis and thereby promotes survival [16]. The reverse transcriptase subunit of telomerase has also been found to be a substrate of PKB, indicating that PKB may also inhibit senescence [219]. An overview of signals emanating from c-kit (and possibly from Flt3) are depicted in *Figure 2* (adapted from [220]), with emphasis on targets downstream of PI-3 kinase and PKB.

Bcl-2 family targets other than Bad have also been shown to be affected by PKB signaling. Mcl-1 has been shown to be a target of KL and interleukin-5 for apoptosis prevention activity via the MEK/MAPK and PI-3K/PKB pathways [179]. Also, PKB has been shown to exert antiapoptotic effects in hematopoietic cells by inhibiting Bax conformational change and its redistribution to the mitochondrial membranes [221]. Further, the pro-survival Bfl-1/A1 has been shown to be a transcriptional target of the transcription factor NF- $\kappa$ B [222], which is activated via the phosphorylation of IKK by PKB, as mentioned above. Activating transcription factor 2 (ATF-2) activities are also reduced by PKB phosphorylation, as is apoptosis signal-regulating kinase 1 (ASK1), which is a c-Jun N-terminal kinase (JNK) activator [223]. Finally, the transcription factor CREB has been shown to be activated by PKB [224].





**Figure 2:** Overview of signals downstream of *c-kit*, PI-3 kinase and Akt/PKB.

After PKB activation, the 14-3-3 proteins have been shown to bind and inactivate, not only the proapoptotic Bcl-2 family protein Bad, but also the forkhead transcription factors [210]. In mammalian cells, three members of the forkhead family have been identified as FoxO1, FoxO3 and FoxO4 (also known as FKHR, FKHL1, and AFX, respectively), all at sites of chromosomal rearrangements in certain human tumors [225-229]. The expression of a constitutively active version of PKB within cells is sufficient to induce the phosphorylation and inactivation of all three forkhead isoforms [208,210,230,231], and the phosphorylation of forkheads can be blocked with the PI-3 kinase inhibitors wortmannin and LY294002 [232]. A mutant of FoxO3 in which all three sites of PKB phosphorylation were converted to alanine was localized to the nucleus even in the presence of survival factors, indicating that the cytoplasmic retention of FoxO3 by 14-3-3 proteins is directly linked to its phosphorylation of PKB.

FoxO3 has also been found to bind to sites present in the promoter of the Fas ligand gene, and to induce expression of a reporter gene driven by the Fas ligand promoter [210]. Thus, when PKB is inactive, forkhead family members may induce endogenous Fas ligand gene transcription, which in its turn binds to the cell surface receptor Fas in an autocrine or paracrine fashion, and triggers a cascade of events leading to apoptosis [16]. FoxO3 has also been shown to induce the expression of the proapoptotic protein Bim [233,234] and the cell cycle regulator p27 [235].

### **Hypoxia and HIF**

Although combinations of cytokines including KL, FL, thrombopoietin (Tpo), and IL-6 have been demonstrated to support the short-term growth of HSCs, extended studies of LT-HSCs have revealed that they may be eventually lost during *in vitro* culture [4,236,237]. Since hematopoiesis occurs in close proximity to the stromal microenvironment, adhesion molecules and environmental cues must be considered, and there is a need to define more precisely the culture conditions required to optimize expansion of HSCs and other primitive progenitor populations. It has been suggested that HSCs reside in hypoxic areas in close proximity to the bone surface [238], and thus hypoxia could offer a HSC niche environment which prevents differentiation and promotes self-renewal. Hypoxia is known to lead to increased epo production and survival of BFU-E, and to induce erythroid maturation [239,240]. Incubation of murine BM cells in hypoxia ensures the maintenance of marrow-repopulating ability together with the expansion of committed progenitors [11-14]. More importantly, there has been a recent report of an 4-fold increase of human LT-HSCs with BM-repopulating activity in severe combined immune deficiency (SCID) mice under hypoxic conditions [241]. The mechanisms behind these effects have not yet been elucidated, but hypoxia has been shown to activate several pathways involved in apoptosis, such as the inhibitor of apoptosis 2 (IAP2) [242] and the inhibition of GSK-3 by hypoxia-induced activation of PKB [243].

Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis [244]. HIF-1 is a heterodimer composed of an inducibly-expressed HIF-1 $\alpha$  subunit and a constitutively-expressed ARNT (also known as HIF-1 $\beta$ ) subunit [245]. ARNT can also form a heterodimer together with HIF-2 $\alpha$  (also known as EPAS1). HIF-1 $\alpha$  and HIF-2 $\alpha$  are subject to rapid ubiquitination and proteosomal degradation under non-hypoxic conditions [246-248] and this process

is inhibited under hypoxic conditions [249]. Targeted disruption in mice of the HIF-1 $\alpha$  and ARNT genes show a connection between hypoxia and maintenance of HSCs [250]. Mice rendered deficient of the HIF-1 $\alpha$  show impaired proliferation of embryonic multilineage hematopoietic progenitors [251], and ARNT<sup>-/-</sup> embryos exhibit decreased numbers of progenitors in the yolk sac [252]. HIF-2 $\alpha$  has also been shown to be required for normal hematopoiesis in mice, and its loss results in pancytopenia [253]. It was suggested that HIF-2 $\alpha$  has a critical role in maintaining a functional microenvironment in the BM for effective hematopoiesis. Interestingly, HIF-2 $\alpha$  has been shown to be strongly expressed within subsets of BM macrophages [10].

HIF-1 is a substrate for various kinase pathways including PI-3K and the MAP kinases ERK and p38 [254], and it has been suggested that activation of PKB promotes stabilization and accumulation of HIF-1 $\alpha$  [255]. ARNT has also been shown to contain a PKB consensus phosphorylation site [16]. Hypoxia-induced overexpression of vascular endothelial growth factor (VEGF) is inhibited in dominant negative mutants of PI-3 kinase and PKB, and it has been suggested that this is dependent on HIF-1 regulation [256]. It is interesting to note in this context that VEGF in hematopoiesis is likely to maintain survival of hematopoietic progenitors through the activation of antiapoptotic pathways [257,258]. PKB might act directly on HIF-1, but it has also been suggested that downstream targets of PKB like the downstream kinase FRAP/mTOR (FKBP-rapamycin-associated protein/mammalian target of rapamycin) is involved [259]. Also, the forkhead transcription factor FoxO4 has been shown to induce the down-regulation of HIF-1 $\alpha$  [260].

## **PRESENT INVESTIGATION**

### **Comparison of induction of Bcl-2 family proteins by IL-3, KL and FL (Paper I)**

In the first paper, we wanted to study early hematopoietic cytokines and their effects on cell survival. Since the receptor for KL is expressed on and has been shown to be a major survival factor for the earliest HSCs, our main focus was on this cytokine, but IL-3 and FL have also been shown to have effects on HSCs and progenitor cells. By alternating the growth conditions for the IL-3 dependent multipotent cell line FDCP-mix (mouse BM-derived cells) between IL-3 at 200 U/ml and IL-3 at 1 U/ml together with KL (100 ng/ml), we established a KL-responsive variant cell line (93.1). To be able to compare the effects of IL-3, KL, and FL, we further infected another progenitor cell line, FDC-P1, with a retroviral construct carrying the coding sequence for the receptor of FL. This cell line was denoted FDC-P1/flt3.

Initially, we found by Western blot analysis that all three cytokines induced phosphorylation of the PI-3 kinase downstream target PKB in FDC-P1/flt3 cells. This phosphorylation of PKB by FL had not been shown previously. By adding LY294002, an inhibitor for PI-3 kinase, this phosphorylation was abrogated, indicating that the PI-3 kinase was the upstream target for all three cytokines. By use of Annexin V staining and flow cytometry to determine the proportions of dead cells, it was revealed that all three cytokines could maintain the cells for a limited time period, but after blockage of the PI-3 signaling, the cells incubated with KL became apoptotic. Survival of the cells incubated with IL-3 and FL was also inhibited by LY294002, but not to the same extent as with KL. At lower concentrations of LY294002, with continued strong inhibition of KL-mediated survival, no significant effect was seen on cells incubated with IL-3 or FL. Thus, despite similar effects on PKB phosphorylation, IL-3 and FL are able to induce alternative survival pathway not linked to the antiapoptotic effects mediated via PKB. When we repeated these experiments with inhibitors for the MAPK pathway, PD98059 and U0126, no major effects could be seen on survival. Phosphorylation of the MAPK target ERK was inhibited, indicating that the inhibitors were functional.

We continued by looking at the Bcl-2 family proteins. By using Western blot, we found that the antiapoptotic mechanism induced by KL did not involve Bcl-2, Bcl-x<sub>L</sub> or Mcl-1, and this was confirmed at mRNA level for Bcl-2 and Bcl-x<sub>L</sub>. In contrast, all three proteins were upregulated after IL-3 stimulation and we showed that the regulation was at the transcriptional level. The mode of action of FL was similar to IL-3, although

with slower kinetics for Bcl-2 mRNA, and not with as high induction of Bcl-x<sub>L</sub> mRNA as seen with IL-3. The major difference was that FL could not induce Mcl-1 protein expression. The expression of Bcl-2 family proteins was shown not to be mediated by PI-3 kinase. We also obtained similar results for IL-3 and KL in the FDCP-mix 93.1 cell line and murine Lin<sup>-</sup> BM-derived cells. Thus, it was confirmed that KL does not induce Bcl-2 family proteins, and its pro-survival signaling is susceptible to PI-3 kinase inhibition.

The conclusion from this paper was that FL has similar roles in the maintenance of the progenitor cell lines as IL-3 by upregulating Bcl-2 family proteins, while the antiapoptotic properties of KL would have to be further investigated.

#### **Activation of Akt/PKB and inactivation of FoxO3 by KL (Paper II)**

In this paper we wanted to elucidate the downstream targets important for the survival signals elicited by c-kit activation and whether this was linked to PI-3 kinase and PKB. PKB has in its turn been shown to inactivate the forkhead transcription factors, FoxO1, FoxO3, and FoxO4, known to regulate apoptosis. Initially, by Western blot analysis we showed that PKB is phosphorylated in FDCP-mix 93.1 cells after IL-3 and KL stimulation, and the effects of KL on survival was shown to be blocked by the PI-3 kinase inhibitor LY294002. We then showed that KL phosphorylated FoxO3 and to some extent FoxO1, but not FoxO4, and this phosphorylation was PI-3 kinase-dependent. By use of immunofluorescence and subcellular fractionation, we found that FoxO3 is translocated out of the nucleus after KL-stimulation, and this was shown to be PI-3 kinase dependent.

We further infected FDC-P1 cells by retroviral gene transfer to overexpress an inducible FoxO3. After addition of tamoxifen, which induces the activity of the triple-mutated form of FoxO3 by translocating it to the nucleus, apoptosis was induced, and these results were obtained despite the presence of KL. Also, triple-mutated FoxO3 was able to inhibit the colony formation of BM-derived Lin<sup>-</sup> progenitors, either in the presence of KL alone for myeloid colony formation, or epo and KL in combination for erythroid colony formation. In these cells only FoxO3 was phosphorylated after addition of KL, whereas FoxO1 and FoxO4 were not.

The conclusion from this paper was that FoxO3 is involved in KL-mediated survival of hematopoietic progenitors.

### **Antiapoptotic effects of Bcl-2 and Akt/PKB in combination with KL (Paper III)**

In this study, we compared the effects of PKB and Bcl-2 in the FDC-P1 cell line, either alone or in combination. To begin with, FDC-P1 cells were transfected with wild type PKB (wtPKB) or a kinase dead variant of PKB (K179M), which is mutated in its ATP binding site. This kinase dead form has previously been shown to inhibit endogenous PKB [261]. After selection for successfully transfected cells and subsequent Annexin V staining and flow cytometry, we found that more cells expressing K179M were apoptotic compared to cells transfected with wtPKB. Thus PKB seemed to mediate antiapoptotic signals in FDC-P1 cells. Overexpression of Bcl-2 and to a lower extent PKB, was shown to improve survival in selected clones, and this could be further enhanced by addition of KL. These effects were not due to increased proliferation, as measured by MTT-assay, but rather due to sustained mitochondrial potential. The mitochondrial integrity, measured by rhodamine-1,2,3 staining, was clearly increased in Bcl-2 expressing cells, whereas introduction of PKB only led to partial enhancement. Similar results were obtained when we overexpressed wtPKB or a mutated form of PKB (E40K), which has an amino acid substitution at its PH domain. This mutation increases the affinity for phospholipids, which has been shown to lead to increased activity [261]. When PKB was introduced in Bcl-2 expressing cells, no further protection from apoptosis could be seen, although the mitochondrial integrity was slightly enhanced. However, the combination of PKB and Bcl-2 did not suffice to reach the mitochondrial potential of Bcl-2 expressing cells incubated with KL.

The data from this study suggest that a combination of KL and Bcl-2 enhances survival of hematopoietic progenitors, but enforced expression of active PKB together with Bcl-2 seemed not to be a sufficient substitution. In future studies it would be of importance to further investigate other downstream signals of PI-3 kinase that might be responsible for the survival effects seen with KL.

#### **Antiapoptotic effects of hypoxia in combination with KL and early acting cytokines (Paper IV)**

Hypoxia has recently been inferred to be involved in the maintenance of hematopoietic stem and progenitor cells. Survival of FDCP-mix 93.1 was shown by Annexin V staining to be increased in low oxygen tension, when incubated with KL or suboptimal concentrations of IL-3 (0.2 U/ml), whereas survival in the presence of high concentrations of IL-3 (200 U/ml) remained the same independently of oxygen level (1%, 5% or 20%). FDCP-mix differentiation induced by G-, M- and GM-CSF was similar when the cells were incubated in 1% or 20% oxygen, as shown by Gr-1 and Mac-1 expression in FACS analysis. Surprisingly, when kept in the presence of IL-3 (normally needed for FDCP-mix maintenance), and hypoxia, the number of differentiated cells increased. Thus, hypoxia induced differentiation in the progenitor cell line.

In a clonal assay using the mononuclear fraction from mouse BM incubated in the presence of IL-1, IL-3 and KL for 4 days, and subsequently seeded in IL-3 and epo, the number of pre-CFC<sub>multi</sub> were increased more than twice in hypoxia compared to 20% oxygen, whereas the number of CFU-C were higher in the normoxic cultures. When we used the Lin<sup>-</sup>Sca<sup>+</sup>Kit<sup>+</sup> fraction from mouse BM and incubated for 4 days in KL, FL, IL-3, IL-6, epo, and G-CSF, which has been shown to support partial rescue of LT-HSC [131], the level of expansion of cells was greater in hypoxia than under normoxic conditions (7.1-fold compared to 3.2-fold). Moreover, the frequency of HPP-CFCs increased four-fold under hypoxia compared to the original numbers of HPP-CFC present in the Lin<sup>-</sup>Sca<sup>+</sup>Kit<sup>+</sup> fraction without any preincubation, whereas the frequency decreased under normoxia. Thus, this indicates that self-renewal of the HPP-CFCs had occurred under hypoxic conditions.

In conclusion, we show in this paper that maintenance of multipotent BM progenitor cells and HSCs is dependent on combination of factors (e.g., KL and low oxygen tension) and that self-renewal of early HSCs is favored by hypoxia.

## DISCUSSION

In this thesis, we have focused on the signaling pathways important for the maintenance and survival of HSCs and progenitor cells. In a clinical aspect, it would be beneficial to elucidate how self-renewal and expansion could occur *in vitro*, since BM transplantation techniques would be improved, and life-long gene therapy would be feasible. Several studies have indicated that certain cytokines in combination are essential to inhibit apoptosis and differentiation, including KL, FL, Tpo, IL-3, IL-6, and IL-11 [4,118,262-266]. When added as single factors, however, these cytokines have little or no effect, although KL has been found to increase the survival of hematopoietic progenitor cells [118,262,267,268]. The ability of cells to escape the apoptotic machinery can be mediated by activation of antiapoptotic members of the Bcl-2 family or by inhibition of the proapoptotic proteins of the same family. Also, the activation of PI-3 kinase is a major intracellular signal transduction pathway by which many cytokines can prevent apoptosis.

There is also the possibility that regulation of the cell cycle and/or general metabolism are important for the maintenance of HSC [269,270]. Further, death-inducing receptors could play a role [183,184]. More importantly, the factors that prevent differentiation are still obscure. For example, suppression of apoptosis by overexpressing Bcl-2 still allows differentiation of a multipotent hematopoietic cell line in the absence of added growth factors [92]. The limited increase in HSCs in the BM of Bcl-2 transgenic mice indicates that HSCs, despite their resistance to apoptosis, are not simply accumulating in ever larger numbers, but are still subject to regulation [153]. The limits on the increase of HSC numbers probably reflect a limit in the HSC supporting microenvironment, the HSC niche.

A “two signal model” was recently presented by Domen and Weissman [117], which suggests that two separate signals are necessary to prevent apoptosis in HSCs. They found that high levels of Bcl-2 expression did not prevent rapid death under serum-free conditions, although it did so in the presence of serum. A large number of cytokines were tested for their ability to support survival of the Bcl-2 overexpressing cells in the absence of serum, including IL-1, IL-2, IL-4, IL-6, IL-7; IL-11, FL, KL, G-CSF, GM-CSF, TNF $\alpha$ , TGF- $\beta$ , MIP-1 $\alpha$ , BMP-4, LIF, OSM, epo, Tpo, bFGF, EGF, and VEGF. Apart from KL, the only effect seen was a very limited response to Tpo, and cell numbers never exceeded input numbers. When incubated with KL, the cells



were increased in number. However, the cells did not maintain their phenotype but differentiated, primarily into early myeloid cells.

That KL-induced protection against apoptosis employs a separate biochemical pathway other than Bcl-2 has been reported earlier [271]. It was thus suggested that the two pathways synergized in expansion of differentiating progenitors, without the expansion of HSCs by self-renewal. Still, the question remained what signals were activated by KL that prevented cell death, and one of the putative targets could be PKB. A comparison of PKB- and Bcl-x<sub>L</sub>-dependent cell survival was recently undertaken using interleukin-3-dependent progenitor cells [280]. Expression of constitutively active PKB allowed cells to survive for prolonged periods following growth factor withdrawal, and was comparable in magnitude to the protection provided by Bcl-x<sub>L</sub>. Although both genes prevented cell death, PKB-protected cells could be distinguished from Bcl-x<sub>L</sub>-protected cells on the basis of increased glucose transporter expression, need for glycolytic activity, stabilized mitochondrial potential, and larger cell size.

In our studies, a rather straightforward role of PKB was seen, as presented in paper I and II. In the hematopoietic progenitor cell lines FDC-P1 and FDCP-mix, and BM-derived Lin<sup>-</sup> cells, c-kit signaling could not activate the antiapoptotic Bcl-2 family proteins investigated, which has also been seen in other cell systems [271,272]. Also, as seen at the mRNA level in RNase protection assay, no proapoptotic Bcl-2 family proteins were down-regulated, although it still remains to be seen if cellular localisation, degradation, or conformational change of these occur. For example, it has recently been shown that PKB regulates cell survival and apoptosis by inhibiting Bax conformational change [221]. In any case, PKB is activated by c-kit signaling via activation of PI-3 kinase, and inhibition of PI-3 kinase leads to apoptosis.

In paper III, we also show that expression of kinase dead PKB leads to enhanced cell death compared to cells with overexpression of wtPKB or a constitutive active form of PKB (E40K). We speculated that we could substitute the combination of KL and Bcl-2 with PKB and Bcl-2. A similar approach was recently used in primordial germ cells, where KL-induced survival could be replaced with PKB [273]. Contrary, our results showed that although PKB protected cells from apoptosis, Bcl-2 was superior in antiapoptotic signaling, and the combination of KL and Bcl-2 was superior to the combination of PKB and Bcl-2. It still remains to be seen if the PKB constructs used in paper III has full activity in hematopoietic progenitor cells, as discussed in this paper. One of the construct used had a modification in its PH domain, with increased affinity

for PIs, but additional factors might be crucial. Most of all, there might be a need for further activation of PDK1 for full activity of PKB in some cell systems.

In paper II, we found that KL stimulation leads to phosphorylation of both PKB and FoxO3 in FDCP-mix cells as well as in Lin<sup>-</sup> mouse progenitors. When we infected FDCP-1 cells with an inducible form of transcriptionally active FoxO3, we also showed that FoxO3 inhibited KL-mediated survival, and the same construct suppressed the colony-forming capacity of Lin<sup>-</sup> cells. Thus, this suggests that the regulation of FoxO3 is a critical step in survival of hematopoietic progenitors via c-kit. However, other cytokines (e.g., IL-2, IL-3, IL-6, epo, and Tpo) can also induce phosphorylation of FoxO3 in committed progenitors [235,274-277].

We also demonstrated phosphorylation of FoxO1 in FDCP-mix cells, whereas FoxO4 was unphosphorylated. However, in BM-derived Lin<sup>-</sup> cells, FoxO1 and FoxO4 appeared phosphorylated, even in cytokine-deprived cells. This could be due to activation by factors present in the serum, since several studies have shown that serum can lead to phosphorylation of downstream PKB targets [208,209,230,232]. Moreover, a recent report showed that when human erythroid progenitors were stimulated with epo or KL, this led to phosphorylation of FoxO3 as well as FoxO1 and FoxO4 [278]. Thus, distinct cytokines can lead to phosphorylation of different forkhead family members, depending on what cell type is studied.

In paper IV, we initially speculated whether KL, with its antiapoptotic properties, could in the right physiological environment (hypoxia) support survival to an even higher extent than seen before, and also to be able to prevent differentiation. As shown recently, hypoxia can even increase LT-HSCs reconstitution in SCID mice [241]. In our study the more primitive progenitor cells were supported by the hypoxic conditions, whereas more differentiated cells were actually inhibited under low oxygen pressure. This fits a model, where the HSC niche in the BM is slightly hypoxic, and thus supports the long-term regeneration of the most primitive cells. Recruited and more differentiated cells leave the BM, and thus have optimal survival conditions in normoxic conditions. This would also be a means to eradicate differentiated cells in the BM, thus limit the use of the HSC niche to LT-HSCs only.

Activation of the PI-3 kinase/PKB pathway has been shown to increase expression of HIF-1 $\alpha$ , by negatively regulate FoxO4 [260]. It would be interesting to investigate whether KL signaling and hypoxia synergize in the down-regulation of forkhead transcription factors in hematopoietic cells, and thus increase HIF-1 activity. Also,

recent data indicate that the gene for Pgp is hypoxia responsive, and it would be interesting to find out if the multidrug resistance transporters are mutually regulated by PKB and hypoxia [279].

## **FUTURE STUDIES**

PKB-expressing hematopoietic cells seem to require high levels of extracellular nutrients to support cell survival, whereas cells expressing Bcl-2 family proteins do not [280]. This implies that metabolism is important in the outcome of the destiny of the cells. In our hands, PKB did not affect the mitochondrial potential nearly as much as Bcl-2, and it is tempting to speculate that PKB protects the cells via pathways not involving the mitochondria or cytochrome c release. Activation of PKB have been shown to increase HIF-1 $\alpha$  protein synthesis and transcriptional activity [281], and it has been found that HIF-1 $\alpha$  is involved in the transcriptional activation of genes encoding glycolytic enzymes [282]. It will be interesting to evaluate if HIF-1 $\alpha$  is up-regulated in HSCs during hypoxia, and whether HIF-1 $\alpha$  can be up-regulated at the physiological oxygen levels present in the BM after stimulation of additional signaling pathways.

Lactate and pyruvate have been found to stimulate the accumulation of HIF-1 $\alpha$  [283]. Lactate is formed from pyruvate in cells under hypoxia, and under these conditions the rate of formation of NADH by glycolysis is greater than the rate of its oxidation by the respiratory chain. Continued glycolysis depends on the availability of NAD<sup>+</sup> for the oxidation of glyceraldehyde 3-phosphate, so the accumulation of both NADH and pyruvate is reversed by lactate dehydrogenase, which oxidizes NADH to NAD<sup>+</sup> as it reduces pyruvate to lactate. Thus, the conversion of glucose to lactate does not involve a net oxidation-reduction, and no reactive oxygen species that can induce apoptosis are formed. The plasma membrane of most cells is highly permeable to lactate and pyruvate and both substances can therefore diffuse out of the cell, but much more lactate than pyruvate is carried if there is a high NADH/NAD<sup>+</sup> ratio in the cell [284].

Pyruvate dehydrogenase is the enzyme complex responsible for the entry of pyruvate to the oxidative phosphorylation chain, and it would be interesting to investigate the regulation of this complex in HSCs, and the oxidative phosphorylation activity. There has also been found a positive correlation between the induction of terminal differentiation and reduced lactate production elicited by retinoic acid [285]. Whether Pgp or BCRP are

responsible for protecting HSCs from differentiating hormones, like retinoic acid, and thus enhance self-renewal, remains to be seen. PKB signaling might be involved in this mechanism, since it was suggested in a recent paper that PKB signaling modulate the side population cell phenotype by regulating the expression of BCRP [286].

The importance of hexokinase involvement in the survival signals mediated by PKB would also be worthwhile studying, not only in its regulation of glycolysis, but also in its activity on the mitochondrial PTP. Activated PKB, like Bcl-2 and Bcl-x<sub>L</sub>, prevents closure of the PTP component VDAC, and PKB does this via the promotion of hexokinase-VDAC interaction at the outer mitochondrial membrane [212]. Interestingly, lithium has been found to induce detachment of hexokinase from mitochondria [287], and after addition of lithium, apoptosis is induced in the hematopoietic progenitor cell line FDCP-mix (unpublished observation). These results can, though, be due to the effects of lithium on the PKB target GSK-3.

In *Figure 3* (adapted from [158]), the relations between c-kit, PKB, forkhead, Bcl-2, hypoxia and metabolism are summarized.




Figure 3: Relations between c-kit, Akt/PKB, forkhead, hypoxia and metabolism.

## **SAMMANFATTNING**

Homeostasen, dvs. bibehållandet av ett konstant antal blodceller, pågår genom hela livet och har sitt ursprung från en sällsynt cell som huvudsakligen finns i benmärgen, där den utgör mindre än 1 cell på 10000-100000. Denna cell, den hematopoetiska stamcellen, ger upphov till alla blodprogenitorer (snabbväxande celler som har bestämt vilken typ av blodceller som de kan utvecklas till) genom differentiering (förändring av cellens egenskaper genom utmognad), samtidigt som den kan fylla på poolen av stamceller på nytt. I en människa som väger 70 kg ersätts varje dag nästan 1 biljon ( $10^{12}$ ) celler i det hematopoetiska systemet och ett viktigt mål med denna avhandling var att kartlägga hur olika faktorer (tex. cytokiner) påverkar stamcellernas celledelning, differentiering och överlevnad. Vi ville även finna de molekylära mekanismerna bakom blodstamcellers och blodprogenitorers överlevnad, vilka fortfarande är ofullständigt kända.

Vi har framför allt undersökt två hematopoetiskt aktiva cytokiner; stamcells faktorn (KL) resp. Flt3-liganden (FL), vilka utövar en signalöverförande förmåga via tyrosinkinasreceptorer (c-kit resp. Flt3-receptorn). Dessa receptorer uttrycks på flera typer av blodceller och har föreslagits vara viktiga vid blodstamcellernas överlevnad och bibehållande. Detta understryks av att c-kit uttrycks på de mest odifferentierade blodstamcellerna, vilka har visat sig kunna nybilda alla celler i blods systemet vid benmärgs transplantationer. Med avseende på FL-medierad överlevnad finns ytterst få rapporter, men överlevnadsproteiner från Bcl-2-familjen har föreslagits vara involverade, medan överlevnad förmedlad via c-kit tycks vara beroende av vilken typ av hematopoetisk cell som har undersökts.

Vi har visat att KL förbättrar överlevnaden av hematopoetiska celler, men att KL inte aktiverar något protein från Bcl-2-familjen. Däremot uppreglerar FL Bcl-2-proteiner, vilket innebär att dessa för blodstamceller två centrala cytokiner tycks aktivera olika vägar för överlevnad. Med hjälp av blockerare för olika signalvägar identifierade vi ett viktigt protein för c-kit-förmedlad överlevnad av blodstamceller, nämligen PI-3 kinas. Nedströms från PI-3 kinas visade sig KL kunna aktivera protein kinaset Akt/PKB, vilketets funktion var nödvändigt för de hematopoetiska cellernas överlevnad. Akt/PKB har vidare visat sig inaktivera den genaktiverande forkhead faktorn FoxO3 och överuttryck av denna faktor visade sig kunna blockera KL-medierad överlevnad.

Vidare studerade vi kombinationer av överuttryck av Akt/PKB och Bcl-2 i blodprogenitorer för att se om överlevnaden kunde förbättras ytterligare. Bcl-2

visade sig vara bättre på att bibehålla cellerna än Akt/PKB och en kombination av överuttryck av Bcl-2 och tillsats av KL gav en bättre överlevnad än överuttryck av Bcl-2 tillsammans med Akt/PKB. Detta tyder på att andra signalvägar nedströms från c-kit än Akt/PKB är viktiga i dessa celler. Det återstår dock att visa hur de mer odifferentierade blodstamcellerna skulle påverkas.

I benmärgen hos möss har det visats att snabbt växande differentierade progenitorceller är lokaliserade nära blodkärlen, medan mer omogna blodstamcellerna är belägna i områden med lägre syretryck (hypoxi) än normalt (normoxi). Hypoxin har också visat sig vara en komponent av den hematopoietiska mikromiljön och en regulator av balansen mellan viloläge och tillväxt. Vad som gjorde detta speciellt intressant för oss var att hypoxi har visat sig kunna aktivera Akt/PKB i vissa celler.

Initialt visade vi att progenitorceller odlade i närvaro av KL har en ökad överlevnad under hypoxi jämfört med normoxi. Vi fortsatte därför med att undersöka celler tagna direkt från benmärg. Vi fann att hypoxi gynnar en bibehållning och en eventuell förökning av blodstamceller, medan progenitorcellerna minskade i antal. Detta fynd skulle kunna vara viktigt kliniskt med avseende på hur man odlar celler vid benmärgs transplantationer.

Ny kunskap kring mekanismerna vid hematopoetiska stam- och progenitorcellers tillväxt, val av differentiering och överlevnad kommer avsevärt att förbättra möjligheten att påverka stamceller till förlängd tillväxt *ex vivo* och på sikt leda till förfinade benmärgstransplantationer och till stamcellsbaserad genterapi. Eftersom blodcancer ofta uppstår på grund av genförändringar i de hematopoetiska stamcellerna kan våra resultat även leda till en bättre förståelse av de biologiska aspekterna på dessa förändringar.

## **ACKNOWLEDGEMENTS**

I would like to thank all past and present people at the division of Molecular Medicine and the department of Laboratory Medicine in Malmö. Especially I would send my gratitude to Jan-Ingvar, who put up with me for four years. He is a great scientist, a very warmhearted person and has a sense of humor that I can really appreciate. Also big hugs to Carolin, who was the backbone of the lab. I am also in debt to the Marias in our group, who helped me when I needed it the most, and I hope the cookies made the hard labor easier. Good luck in the future in Linköping.

I would also thank Paula, Stina and Marie, who shared their working space and telephone without complaining about my expansion tendencies, and the sharing of the incoming jokes. Thanks to Tobbe, my brother in arms (and golf when there was time), and to the rest of the innebandy gang that I did my best to cripple every Monday.

My thoughts also goes to Cathelijne and Ulf, who I really missed when you left the lab, and Ulrika, who shared my anguish writing a thesis. A big hug to the girls (and nowadays boys also) at the division of Pathology, especially the always smiling Åsa and Maria, and Göran, who always seemed to be on the winning team in innebandy.

Thanks also to the division of Experimental Pathology, especially the water-boy Oliver, the cunning Karim, the always happy Christian (davs), the always so cool Ramin, and John, Janna and Simone for the interesting conversations we always seemed to get into instead of working with the computers.

Outside the department there is Alex, and my former colleagues Petter, Anna M, Hanna, Anette, Annamaria and especially Sanna for sharing the ups and downs in science. Erik and Martin, for being the best of friends and for all the good times.

To all my friends, thanks for the support throughout the long years.

To my family; my mother, brother, sister, Göran and most of all little Magnus-you have a secure place in my heart. To Maria and Anton, for letting me be a part of your family. Thanks to Sussie, without you nothing would be possible and I will always love you.

The work presented here was funded by the Malmö University Hospital and its research funds, the order Urania (Landskrona), the Swedish Cancer Society, the Children's Cancer Foundation of Sweden, HKH Kronprinsessan Lovisas förening för barnsjukvård, Stiftelsen för Blodsjukdomars bekämpande, Axel Tielmans Minnesfond, Crafoordska stiftelsen, and the Magnus Bergvalls, the Inga och John Hains, the Hans von Kantzows, and the Anna Lisa och Sven-Eric Lundgrens Stiftelser.



## REFERENCES

1. Harrison DE, Astle CM, Lerner C (1988) Number and continuous proliferative pattern of transplanted primitive immunohematopoietic stem cells. *Proc Natl Acad Sci U S A* 85:822
2. Metcalf D (1993) Hematopoietic regulators: redundancy or subtlety? *Blood* 82:3515
3. Ogawa M (1993) Differentiation and proliferation of hematopoietic stem cells. *Blood* 81:2844
4. Lyman SD, Jacobsen SE (1998) c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. *Blood* 91:1101
5. Watt FM, Hogan BL (2000) Out of Eden: stem cells and their niches. *Science* 287:1427
6. Whetton AD, Spooner E (1998) Role of cytokines and extracellular matrix in the regulation of haemopoietic stem cells. *Curr Opin Cell Biol* 10:721
7. Kovach NL, Lin N, Yednock T, Harlan JM, Broudy VC (1995) Stem cell factor modulates avidity of alpha 4 beta 1 and alpha 5 beta 1 integrins expressed on hematopoietic cell lines. *Blood* 85:159
8. Kapur R, Cooper R, Zhang L, Williams DA (2001) Cross-talk between alpha(4)beta(1)/alpha(5)beta(1) and c-Kit results in opposing effect on growth and survival of hematopoietic cells via the activation of focal adhesion kinase, mitogen-activated protein kinase, and Akt signaling pathways. *Blood* 97:1975
9. Gu Y, Sorokin L, Durbeek M, Hjalt T, Jonsson JI, Ekblom M (1999) Characterization of bone marrow laminins and identification of alpha5- containing laminins as adhesive proteins for multipotent hematopoietic FDCP-Mix cells. *Blood* 93:2533
10. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. *Am J Pathol* 157:411
11. Cipolleschi MG, Dello Sbarba P, Olivotto M (1993) The role of hypoxia in the maintenance of hematopoietic stem cells. *Blood* 82:2031
12. Cipolleschi MG, Rovida E, Ivanovic Z, Praloran V, Olivotto M, Dello Sbarba P (2000) The expansion of murine bone marrow cells preincubated in hypoxia as an in vitro indicator of their marrow-repopulating ability. *Leukemia* 14:735
13. Ivanovic Z, Bartolozzi B, Bernabei PA, Cipolleschi MG, Rovida E, Milenkovic P, Praloran V, Dello Sbarba P (2000) Incubation of murine bone marrow cells in hypoxia ensures the maintenance of marrow-repopulating ability together with the expansion of committed progenitors. *Br J Haematol* 108:424
14. Ivanovic Z, Belloc F, Faucher JL, Cipolleschi MG, Praloran V, Dello Sbarba P (2002)

## References

---

- Hypoxia maintains and interleukin-3 reduces the pre-colony-forming cell potential of dividing CD34(+) murine bone marrow cells. *Exp Hematol* 30:67
15. Borner C (2003) The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. *Mol Immunol* 39:615
  16. Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. *Genes Dev* 13:2905
  17. Abramson S, Miller RG, Phillips RA (1977) The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. *J Exp Med* 145:1567
  18. Micklem HS, Ford CE, Evans EP, Gray J (1966) Interrelationships of myeloid and lymphoid cells: studies with chromosome-marked cells transfused into lethally irradiated mice. *Proc R Soc Lond B Biol Sci* 165:78
  19. Capel B, Hawley R, Covarrubias L, Hawley T, Mintz B (1989) Clonal contributions of small numbers of retrovirally marked hematopoietic stem cells engrafted in unirradiated neonatal W/Wv mice. *Proc Natl Acad Sci U S A* 86:4564
  20. Dick JE, Magli MC, Huszar D, Phillips RA, Bernstein A (1985) Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. *Cell* 42:71
  21. Jordan CT, McKearn JP, Lemischka IR (1990) Cellular and developmental properties of fetal hematopoietic stem cells. *Cell* 61:953
  22. Lemischka IR, Raulet DH, Mulligan RC (1986) Developmental potential and dynamic behavior of hematopoietic stem cells. *Cell* 45:917
  23. Snodgrass R, Keller G (1987) Clonal fluctuation within the haematopoietic system of mice reconstituted with retrovirus-infected stem cells. *Embo J* 6:3955
  24. Bradford GB, Williams B, Rossi R, Bertonecello I (1997) Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. *Exp Hematol* 25:445
  25. Cheshier SH, Morrison SJ, Liao X, Weissman IL (1999) In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. *Proc Natl Acad Sci U S A* 96:3120
  26. Weissman IL, Anderson DJ, Gage F (2001) Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. *Annu Rev Cell Dev Biol* 17:387
  27. Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dohse M, Osborne L, Wang X, Finegold M, Weissman IL, Grompe M (2000) Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. *Nat Med* 6:1229
  28. Bjornson CR, Rietze RL, Reynolds BA, Magli MC, Vescovi AL (1999) Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo [see comments].

- Science 283:534
29. Blau HM, Brazelton TR, Weimann JM (2001) The evolving concept of a stem cell: entity or function? *Cell* 105:829
30. Wang X, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Olson S, Grompe M (2003) Cell fusion is the principal source of bone-marrow-derived hepatocytes. *Nature* 422:897
31. Vassilopoulos G, Wang PR, Russell DW (2003) Transplanted bone marrow regenerates liver by cell fusion. *Nature* 422:901
32. Zon LI (1995) Developmental biology of hematopoiesis. *Blood* 86:2876
33. Marshall CJ, Thrasher AJ (2001) The embryonic origins of human haematopoiesis. *Br J Haematol* 112:838
34. Dzierzak E, Medvinsky A, de Bruijn M (1998) Qualitative and quantitative aspects of haematopoietic cell development in the mammalian embryo. *Immunol Today* 19:228
35. Cumano A, Dieterlen-Lievre F, Godin I (1996) Lymphoid potential, probed before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura. *Cell* 86:907
36. Medvinsky A, Dzierzak E (1996) Definitive hematopoiesis is autonomously initiated by the AGM region. *Cell* 86:897
37. Muller AM, Medvinsky A, Strouboulis J, Grosveld F, Dzierzak E (1994) Development of hematopoietic stem cell activity in the mouse embryo. *Immunity* 1:291
38. Valtieri M, Tocci A, Gabbianelli M, Luchetti L, Masella B, Vitelli L, Botta R, Testa U, Condorelli GL, Peschle C (1998) Enforced TAL-1 expression stimulates primitive, erythroid and megakaryocytic progenitors but blocks the granulopoietic differentiation program. *Cancer Res* 58:562
39. Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin SH (1996) The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. *Cell* 86:47
40. Shivdasani RA, Orkin SH (1996) The transcriptional control of hematopoiesis [see comments]. *Blood* 87:4025
41. Robb L, Begley CG (1997) The SCL/TAL1 gene: roles in normal and malignant haematopoiesis. *Bioessays* 19:607
42. Lecuyer E, Herblot S, Saint-Denis M, Martin R, Begley CG, Porcher C, Orkin SH, Hoang T (2002) The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with Sp1. *Blood* 100:2430
43. Kros G, He G, Lefrancois M, Charron F, Romeo PH, Jolicoeur P, Kirsch IR, Nemer M, Hoang T (1998) Transcription factor SCL is required for c-kit expression and c-Kit function in hemopoietic cells. *J Exp Med* 188:439
44. Korblyng M (1999) Collection of allogeneic peripheral blood stem cells.

## References

---

- Baillieres Best Pract Res Clin Haematol 12:41
45. Kronenwett R, Martin S, Haas R (2000) The role of cytokines and adhesion molecules for mobilization of peripheral blood stem cells. *Stem Cells* 18:320
46. Ashman LK (1999) The biology of stem cell factor and its receptor C-kit. *Int J Biochem Cell Biol* 31:1037
47. Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, Williams DE, Lyman SD (1996) Hematologic effects of flt3 ligand in vivo in mice. *Blood* 88:2004
48. Brasel K, McKenna HJ, Charrier K, Morrissey PJ, Williams DE, Lyman SD (1997) Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice. *Blood* 90:3781
49. Ashihara E, Shimazaki C, Sudo Y, Kikuta T, Hirai H, Sumikuma T, Yamagata N, Goto H, Inaba T, Fujita N, Nakagawa M (1998) FLT-3 ligand mobilizes hematopoietic primitive and committed progenitor cells into blood in mice. *Eur J Haematol* 60:86
50. Liu H, Verfaillie CM (2002) Myeloid-lymphoid initiating cells (ML-IC) are highly enriched in the rhodamine-c-kit(+)/CD33(-)/CD38(-) fraction of umbilical cord CD34(+) cells. *Exp Hematol* 30:582
51. Weissman IL (2002) The road ended up at stem cells. *Immunol Rev* 185:159
52. Osawa M, Hanada K, Hamada H, Nakauchi H (1996) Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. *Science* 273:242
53. Randall TD, Lund FE, Howard MC, Weissman IL (1996) Expression of murine CD38 defines a population of long-term reconstituting hematopoietic stem cells. *Blood* 87:4057
54. Terstappen LW, Huang S, Safford M, Lansdorp PM, Loken MR (1991) Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. *Blood* 77:1218
55. Petzer AL, Hogge DE, Lansdorp PM, Reid DS, Eaves CJ (1996) Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. *Proc Natl Acad Sci U S A* 93:1470
56. Zanjani ED, Almeida-Porada G, Livingston AG, Flake AW, Ogawa M (1998) Human bone marrow CD34- cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells [see comments]. *Exp Hematol* 26:353
57. Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Miura Y, Suda T (1991) Enrichment and characterization of murine hematopoietic stem cells that express c-kit molecule. *Blood* 78:1706
58. Spangrude GJ, Heimfeld S, Weissman IL (1988) Purification and characterization of mouse hematopoietic stem cells. *Science* 241:58
59. Uchida N, Tsukamoto A, He D, Frieri AM, Scollay R, Weissman IL (1998) High doses of

- purified stem cells cause early hematopoietic recovery in syngeneic and allogeneic hosts. *J Clin Invest* 101:961
60. Fleming WH, Alpern EJ, Uchida N, Ikuta K, Spangrude GJ, Weissman IL (1993) Functional heterogeneity is associated with the cell cycle status of murine hematopoietic stem cells. *J Cell Biol* 122:897
61. Phillips RL, Reinhart AJ, Van Zant G (1992) Genetic control of murine hematopoietic stem cell pool sizes and cycling kinetics. *Proc Natl Acad Sci U S A* 89:11607
62. Fibbe WE, Zijlmans JM, Willemze R (1997) Differential short-term and long-term repopulating ability of stem cell subsets in mice. *Stem Cells* 15 Suppl 1:47
63. Chaudhary PM, Roninson IB (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. *Cell* 66:85
64. Bunting KD, Galipeau J, Topham D, Benaim E, Sorrentino BP (1998) Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. *Blood* 92:2269
65. Bunting KD, Zhou S, Lu T, Sorrentino BP (2000) Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo. *Blood* 96:902
66. Smeets ME, Raymakers RA, Vierwinden G, Pennings AH, Wessels H, de Witte T (1999) Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance. *Blood* 94:2414
67. Kizaki M, Ueno H, Yamazoe Y, Shimada M, Takayama N, Muto A, Matsushita H, Nakajima H, Morikawa M, Koeffler HP, Ikeda Y (1996) Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. *Blood* 87:725
68. Matsushita H, Kizaki M, Kobayashi H, Ueno H, Muto A, Takayama N, Awaya N, Kinjo K, Hattori Y, Ikeda Y (1998) Restoration of retinoid sensitivity by MDR1 ribozymes in retinoic acid-resistant myeloid leukemic cells. *Blood* 91:2452
69. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K (2002) The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. *Clin Cancer Res* 8:22
70. Guo Y, Lubbert M, Engelhardt M (2003) CD34- hematopoietic stem cells: current concepts and controversies. *Stem Cells* 21:15
71. Glimm H, Oh IH, Eaves CJ (2000) Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not

- reenter G(0). *Blood* 96:4185
72. Yamaguchi M, Hirayama F, Kanai M, Sato N, Fukazawa K, Yamashita K, Sawada K, Koike T, Kuwabara M, Ikeda H, Ikebuchi K (2001) Serum-free coculture system for ex vivo expansion of human cord blood primitive progenitors and SCID mouse-reconstituting cells using human bone marrow primary stromal cells. *Exp Hematol* 29:174
73. Siminovitch L, McCulloch EA, Till JE (1963) The Distribution of Colony-Forming Cells among Spleen Colonies. *J Cell Physiol* 62:327
74. Till JE, Mc CE (1961) A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. *Radiat Res* 14:213
75. Jones RJ, Wagner JE, Celano P, Zicha MS, Sharkis SJ (1990) Separation of pluripotent haematopoietic stem cells from spleen colony-forming cells. *Nature* 347:188
76. Williams DA, Lemischka IR, Nathan DG, Mulligan RC (1984) Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. *Nature* 310:476
77. Keller G, Paige C, Gilboa E, Wagner EF (1985) Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors. *Nature* 318:149
78. Eaves CJ, Cashman JD, Sutherland HJ, Otsuka T, Humphries RK, Hogge DE, Lansdorp PL, Eaves AC (1991) Molecular analysis of primitive hematopoietic cell proliferation control mechanisms. *Ann N Y Acad Sci* 628:298
79. Slanicka Krieger M, Nissen C, Manz CY, Toksoz D, Lyman SD, Wodnar-Filipowicz A (1998) The membrane-bound isoform of stem cell factor synergizes with soluble flt3 ligand in supporting early hematopoietic cells in long-term cultures of normal and aplastic anemia bone marrow. *Exp Hematol* 26:365
80. Ramsfjell V, Bryder D, Bjorgvinsdottir H, Kornfalt S, Nilsson L, Borge OJ, Jacobsen SE (1999) Distinct requirements for optimal growth and In vitro expansion of human CD34(+)CD38(-) bone marrow long-term culture-initiating cells (LTC-IC), extended LTC-IC, and murine in vivo long-term reconstituting stem cells. *Blood* 94:4093
81. Carlo-Stella C, Regazzi E, Garau D, Mangoni L, Rizzo MT, Bonati A, Dotti G, Almici C, Rizzoli V (1996) Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells. *Br J Haematol* 93:551
82. Brandt JE, Bhalla K, Hoffman R (1994) Effects of interleukin-3 and c-kit ligand on the survival of various classes of human hematopoietic progenitor cells. *Blood* 83:1507
83. Muench MO, Schneider JG, Moore MA (1992) Interactions among colony-stimulating factors, IL-1 beta, IL-6, and kit- ligand in the regulation of primitive murine hematopoietic cells. *Exp Hematol* 20:339
84. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. *Nature* 414:105

85. Weissman IL (2000) Stem cells: units of development, units of regeneration, and units in evolution. *Cell* 100:157
86. Kondo M, Weissman IL, Akashi K (1997) Identification of clonogenic common lymphoid progenitors in mouse bone marrow. *Cell* 91:661
87. Akashi K, Traver D, Miyamoto T, Weissman IL (2000) A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. *Nature* 404:193
88. Kondo M, Scherer DC, Miyamoto T, King AG, Akashi K, Sugamura K, Weissman IL (2000) Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines. *Nature* 407:383
89. King AG, Kondo M, Scherer DC, Weissman IL (2002) Lineage infidelity in myeloid cells with TCR gene rearrangement: a latent developmental potential of proT cells revealed by ectopic cytokine receptor signaling. *Proc Natl Acad Sci U S A* 99:4508
90. Metcalf D (1992) Hemopoietic regulators. *Trends Biochem Sci* 17:286
91. Thornley I, Sutherland R, Wynn R, Nayar R, Sung L, Corpus G, Kiss T, Lipton J, Doyle J, Saunders F, Kamel-Reid S, Freedman M, Messner H (2002) Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss. *Blood* 99:2387
92. Fairbairn LJ, Cowling GJ, Reipert BM, Dexter TM (1993) Suppression of apoptosis allows differentiation and development of a multipotent hemopoietic cell line in the absence of added growth factors. *Cell* 74:823
93. Pharr PN, Ogawa M, Hofbauer A, Longmore GD (1994) Expression of an activated erythropoietin or a colony-stimulating factor 1 receptor by pluripotent progenitors enhances colony formation but does not induce differentiation. *Proc Natl Acad Sci U S A* 91:7482
94. Kaushansky K (1998) Growth factors and hematopoietic cell fate. A new feature: controversies in hematology [In Process Citation]. *Blood* 92:345
95. D'Andrea AD (1994) Hematopoietic growth factors and the regulation of differentiative decisions. *Curr Opin Cell Biol* 6:804
96. Orkin SH (1995) Transcription factors and hematopoietic development. *J Biol Chem* 270:4955
97. Tenen DG, Hromas R, Licht JD, Zhang DE (1997) Transcription factors, normal myeloid development, and leukemia. *Blood* 90:489
98. Hara T, Miyajima A (1996) Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis. *Stem Cells* 14:605
99. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. *Biochem J* 334:297
100. Miller CL, Eaves CJ (1997) Expansion in vitro of adult murine hematopoietic stem cells



## References

---

- with transplantable lympho-myeloid reconstituting ability.  
Proc Natl Acad Sci U S A 94:13648
101. Varnum-Finney B, Xu L, Brashem-Stein C, Nourigat C, Flowers D, Bakkour S, Pear WS, Bernstein ID (2000) Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. *Nat Med* 6:1278
  102. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL (2003) A role for Wnt signalling in self-renewal of haematopoietic stem cells. *Nature* 423:409
  103. Wodarz A, Nusse R (1998) Mechanisms of Wnt signaling in development. *Annu Rev Cell Dev Biol* 14:59
  104. Huelsken J, Behrens J (2002) The Wnt signalling pathway. *J Cell Sci* 115:3977
  105. Morrison SJ, Shah NM, Anderson DJ (1997) Regulatory mechanisms in stem cell biology. *Cell* 88:287
  106. Lee HW, Blasco MA, Gottlieb GJ, Horner JW, 2nd, Greider CW, DePinho RA (1998) Essential role of mouse telomerase in highly proliferative organs. *Nature* 392:569
  107. Broudy VC (1997) Stem cell factor and hematopoiesis. *Blood* 90:1345
  108. Geissler EN, Ryan MA, Housman DE (1988) The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. *Cell* 55:185
  109. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A (1988) The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. *Nature* 335:88
  110. Huang E, Nocka K, Beier DR, Chu TY, Buck J, Lahm HW, Wellner D, Leder P, Besmer P (1990) The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. *Cell* 63:225
  111. Williams DE, Eisenman J, Baird A, Rauch C, Van Ness K, March CJ, Park LS, Martin U, Mochizuki DY, Boswell HS, et al. (1990) Identification of a ligand for the c-kit proto-oncogene. *Cell* 63:167
  112. Zsebo KM, Wypych J, McNiece IK, Lu HS, Smith KA, Karkare SB, Sachdev RK, Yuschenkoff VN, Birkett NC, Williams LR, et al. (1990) Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver--conditioned medium. *Cell* 63:195
  113. Copeland NG, Gilbert DJ, Cho BC, Donovan PJ, Jenkins NA, Cosman D, Anderson D, Lyman SD, Williams DE (1990) Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. *Cell* 63:175
  114. Flanagan JG, Leder P (1990) The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. *Cell* 63:185
  115. Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman J, Rauch C, March CJ,



- Boswell HS, Gimpel SD, Cosman D, et al. (1990) Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. *Cell* 63:235
116. Martin FH, Suggs SV, Langley KE, Lu HS, Ting J, Okino KH, Morris CF, McNiece IK, Jacobsen FW, Mendiaz EA, et al. (1990) Primary structure and functional expression of rat and human stem cell factor DNAs. *Cell* 63:203
117. Domen J, Weissman IL (2000) Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, Kitl/c-Kit signaling the other. *J Exp Med* 192:1707
118. Keller JR, Ortiz M, Ruscetti FW (1995) Steel factor (c-kit ligand) promotes the survival of hematopoietic stem/progenitor cells in the absence of cell division. *Blood* 86:1757
119. Miura N, Okada S, Zsebo KM, Miura Y, Suda T (1993) Rat stem cell factor and IL-6 preferentially support the proliferation of c-kit-positive murine hemopoietic cells rather than their differentiation. *Exp Hematol* 21:143
120. Ramsfjell V, Borge OJ, Veiby OP, Cardier J, Murphy MJ, Jr., Lyman SD, Lok S, Jacobsen SE (1996) Thrombopoietin, but not erythropoietin, directly stimulates multilineage growth of primitive murine bone marrow progenitor cells in synergy with early acting cytokines: distinct interactions with the ligands for c-kit and FLT3. *Blood* 88:4481
121. Tsuji K, Lyman SD, Sudo T, Clark SC, Ogawa M (1992) Enhancement of murine hematopoiesis by synergistic interactions between steel factor (ligand for c-kit), interleukin-11, and other early acting factors in culture. *Blood* 79:2855
122. Takeda S, Shimizu T, Rodewald HR (1997) Interactions between c-kit and stem cell factor are not required for B- cell development in vivo. *Blood* 89:518
123. Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D (1991) Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. *Oncogene* 6:1641
124. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR (1991) A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. *Cell* 65:1143
125. Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. *Blood* 100:1532
126. Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR, et al. (1993) Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. *Cell* 75:1157
127. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J, et al. (1994) Ligand for FLT3/FLK2 receptor tyrosine

## References

---

- kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. *Nature* 368:643
128. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR (1995) Targeted disruption of the *flk2/flt3* gene leads to deficiencies in primitive hematopoietic progenitors. *Immunity* 3:147
129. McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E, Maliszewski CR, Lynch DH, Smith J, Pulendran B, Roux ER, Teepe M, Lyman SD, Peschon JJ (2000) Mice lacking *flt3* ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. *Blood* 95:3489
130. Sitnicka E, Bryder D, Theilgaard-Monch K, Buza-Vidas N, Adolfsson J, Jacobsen SE (2002) Key role of *flt3* ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool. *Immunity* 17:463
131. Adolfsson J, Borge OJ, Bryder D, Theilgaard-Monch K, Astrand-Grundstrom I, Sitnicka E, Sasaki Y, Jacobsen SE (2001) Upregulation of *Flt3* expression within the bone marrow *Lin*(-)*Sca1*(+)*c-kit*(+) stem cell compartment is accompanied by loss of self-renewal capacity. *Immunity* 15:659
132. Christensen JL, Weissman IL (2001) *Flk-2* is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. *Proc Natl Acad Sci U S A* 98:14541
133. Gotze KS, Ramirez M, Tabor K, Small D, Matthews W, Civin CI (1998) *Flt3*<sup>high</sup> and *Flt3*<sup>low</sup> *CD34*<sup>+</sup> progenitor cells isolated from human bone marrow are functionally distinct. *Blood* 91:1947
134. Lyman SD, James L, Escobar S, Downey H, de Vries P, Brasel K, Stocking K, Beckmann MP, Copeland NG, Cleveland LS, et al. (1995) Identification of soluble and membrane-bound isoforms of the murine *flt3* ligand generated by alternative splicing of mRNAs. *Oncogene* 10:149
135. Solanilla A, Grosset C, Lemercier C, Dupouy M, Mahon FX, Schweitzer K, Reiffers J, Weksler B, Ripoche J (2000) Expression of *Flt3*-ligand by the endothelial cell. *Leukemia* 14:153
136. Broxmeyer HE, Lu L, Cooper S, Ruggieri L, Li ZH, Lyman SD (1995) *Flt3* ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. *Exp Hematol* 23:1121
137. Hudak S, Hunte B, Culpepper J, Menon S, Hannum C, Thompson-Snipes L, Rennick D (1995) *FLT3/FLK2* ligand promotes the growth of murine stem cells and the expansion of colony-forming cells and spleen colony-forming units. *Blood* 85:2747
138. Jacobsen SE, Okkenhaug C, Myklebust J, Veiby OP, Lyman SD (1995) The *FLT3* ligand potently and directly stimulates the growth and expansion of primitive murine bone

- marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. *J Exp Med* 181:1357
139. Jacobsen SE, Veiby OP, Myklebust J, Okkenhaug C, Lyman SD (1996) Ability of flt3 ligand to stimulate the in vitro growth of primitive murine hematopoietic progenitors is potently and directly inhibited by transforming growth factor-beta and tumor necrosis factor-alpha. *Blood* 87:5016
140. Banu N, Deng B, Lyman SD, Avraham H (1999) Modulation of haematopoietic progenitor development by FLT-3 ligand. *Cytokine* 11:679
141. Veiby OP, Jacobsen FW, Cui L, Lyman SD, Jacobsen SE (1996) The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta. *J Immunol* 157:2953
142. Nicholls SE, Winter S, Mottram R, Miyan JA, Whetton AD (1999) Flt3 ligand can promote survival and macrophage development without proliferation in myeloid progenitor cells. *Exp Hematol* 27:663
143. Yonemura Y, Ku H, Lyman SD, Ogawa M (1997) In vitro expansion of hematopoietic progenitors and maintenance of stem cells: comparison between FLT3/FLK-2 ligand and KIT ligand. *Blood* 89:1915
144. Hjertson M, Sundstrom C, Lyman SD, Nilsson K, Nilsson G (1996) Stem cell factor, but not flt3 ligand, induces differentiation and activation of human mast cells. *Exp Hematol* 24:748
145. Veiby OP, Lyman SD, Jacobsen SE (1996) Combined signaling through interleukin-7 receptors and flt3 but not c-kit potently and selectively promotes B-cell commitment and differentiation from uncommitted murine bone marrow progenitor cells. *Blood* 88:1256
146. Linnekin D (1999) Early signaling pathways activated by c-Kit in hematopoietic cells. *Int J Biochem Cell Biol* 31:1053
147. Curti A, Fogli M, Ratta M, Tura S, Lemoli RM (2001) Stem cell factor and FLT3-ligand are strictly required to sustain the long-term expansion of primitive CD34+DR- dendritic cell precursors. *J Immunol* 166:848
148. Domen J, Weissman IL (1999) Self-renewal, differentiation or death: regulation and manipulation of hematopoietic stem cell fate. *Mol Med Today* 5:201
149. Cleary ML, Smith SD, Sklar J (1986) Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. *Cell* 47:19
150. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM (1984) Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. *Science* 226:1097

## References

---

151. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature* 348:334
152. Domen J, Gandy KL, Weissman IL (1998) Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation. *Blood* 91:2272
153. Domen J, Cheshier SH, Weissman IL (2000) The role of apoptosis in the regulation of hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation potential. *J Exp Med* 191:253
154. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ (1991) BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. *Proc Natl Acad Sci U S A* 88:6961
155. Kamada S, Shimono A, Shinto Y, Tsujimura T, Takahashi T, Noda T, Kitamura Y, Kondoh H, Tsujimoto Y (1995) bcl-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. *Cancer Res* 55:354
156. Knudson CM, Korsmeyer SJ (1997) Bcl-2 and Bax function independently to regulate cell death. *Nat Genet* 16:358
157. Gross A, McDonnell JM, Korsmeyer SJ (1999) BCL-2 family members and the mitochondria in apoptosis. *Genes Dev* 13:1899
158. Plas DR, Rathmell JC, Thompson CB (2002) Homeostatic control of lymphocyte survival: potential origins and implications. *Nat Immunol* 3:515
159. Adams JM, Cory S (2001) Life-or-death decisions by the Bcl-2 protein family. *Trends Biochem Sci* 26:61
160. Crompton M (1999) The mitochondrial permeability transition pore and its role in cell death. *Biochem J* 341 ( Pt 2):233
161. Adams JM, Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. *Science* 281:1322
162. Green DR, Reed JC (1998) Mitochondria and apoptosis. *Science* 281:1309
163. Ranger AM, Malynn BA, Korsmeyer SJ (2001) Mouse models of cell death. *Nat Genet* 28:113
164. Rathmell JC, Thompson CB (2002) Pathways of apoptosis in lymphocyte development, homeostasis, and disease. *Cell* 109 Suppl:S97
165. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW (1993) MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. *Proc Natl Acad Sci U S A* 90:3516
166. Zhou P, Qian L, Kozopas KM, Craig RW (1997) Mcl-1, a Bcl-2 family member, delays

- the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89:630
167. Zhou P, Qian L, Bieszczad CK, Noelle R, Binder M, Levy NB, Craig RW (1998) Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 92:3226
  168. Shimizu S, Narita M, Tsujimoto Y (1999) Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399:483
  169. Park JR, Bernstein ID, Hockenbery DM (1995) Primitive human hematopoietic precursors express Bcl-x but not Bcl-2. Blood 86:868
  170. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Negishi I, Senju S, Zhang Q, Fujii S, et al. (1995) Massive cell death of immature hematopoietic cells and neurons in Bcl-x- deficient mice. Science 267:1506
  171. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ (1993) Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75:229
  172. Lin EY, Orlofsky A, Wang HG, Reed JC, Prystowsky MB (1996) A1, a Bcl-2 family member, prolongs cell survival and permits myeloid differentiation. Blood 87:983
  173. Hamasaki A, Sendo F, Nakayama K, Ishida N, Negishi I, Hatakeyama S (1998) Accelerated neutrophil apoptosis in mice lacking A1-a, a subtype of the bcl-2-related A1 gene. J Exp Med 188:1985
  174. Sanz C, Benito A, Inohara N, Ekhterae D, Nunez G, Fernandez-Luna JL (2000) Specific and rapid induction of the proapoptotic protein Hrk after growth factor withdrawal in hematopoietic progenitor cells. Blood 95:2742
  175. Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, Munker R, Goodacre A, Savchenko V, Andreeff M (1996) Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood 88:3987
  176. Carson WE, Haldar S, Baiocchi RA, Croce CM, Caligiuri MA (1994) The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. Proc Natl Acad Sci U S A 91:7553
  177. Kapur R, Zhang L (2001) A novel mechanism of cooperation between c-Kit and erythropoietin receptor. Stem cell factor induces the expression of Stat5 and erythropoietin receptor, resulting in efficient proliferation and survival by erythropoietin. J Biol Chem 276:1099
  178. Zeuner A, Pedini F, Signore M, Testa U, Pelosi E, Peschle C, De Maria R (2003) Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins. Blood 102:87

## References

---

179. Huang HM, Huang CJ, Yen JJ (2000) Mcl-1 is a common target of stem cell factor and interleukin-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/Akt pathways. *Blood* 96:1764
180. Niho Y, Asano Y (1998) Fas/Fas ligand and hematopoietic progenitor cells. *Curr Opin Hematol* 5:163
181. Stahnke K, Hecker S, Kohne E, Debatin KM (1998) CD95 (APO-1/FAS)-mediated apoptosis in cytokine-activated hematopoietic cells. *Exp Hematol* 26:844
182. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okamura T, Gondo H, Niho Y (1995) Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. *Blood* 86:883
183. Barcena A, Muench MO, Song KS, Ohkubo T, Harrison MR (1999) Role of CD95/Fas and its ligand in the regulation of the growth of human CD34(++)CD38(-) fetal liver cells. *Exp Hematol* 27:1428
184. Bryder D, Ramsfjell V, Dybedal I, Theilgaard-Monch K, Hogerkorp CM, Adolfsson J, Borge OJ, Jacobsen SE (2001) Self-renewal of multipotent long-term repopulating hematopoietic stem cells is negatively regulated by Fas and tumor necrosis factor receptor activation. *J Exp Med* 194:941
185. Maciejewski J, Selleri C, Anderson S, Young NS (1995) Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. *Blood* 85:3183
186. Kapeller R, Cantley LC (1994) Phosphatidylinositol 3-kinase. *Bioessays* 16:565
187. Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen BS, Cantley LC (1990) Purification and characterization of phosphoinositide 3-kinase from rat liver. *J Biol Chem* 265:19704
188. Rottapel R, Reedijk M, Williams DE, Lyman SD, Anderson DM, Pawson T, Bernstein A (1991) The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor. *Mol Cell Biol* 11:3043
189. Lev S, Givol D, Yarden Y (1991) A specific combination of substrates is involved in signal transduction by the kit-encoded receptor. *Embo J* 10:647
190. Reith AD, Ellis C, Lyman SD, Anderson DM, Williams DE, Bernstein A, Pawson T (1991) Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. *Embo J* 10:2451
191. Fruman DA, Snapper SB, Yballe CM, Davidson L, Yu JY, Alt FW, Cantley LC (1999) Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. *Science* 283:393

192. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M, Mak TW (1998) High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. *Curr Biol* 8:1169
193. Condliffe AM, Hawkins PT (2000) Cell biology. Moving in mysterious ways. *Nature* 404:135
194. Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, Gaffney P, Reese CB, MacDougall CN, Harbison D, Ashworth A, Bownes M (1997) 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the *Drosophila* DSTPK61 kinase. *Curr Biol* 7:776
195. Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. *Proc Natl Acad Sci U S A* 96:4240
196. Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J Biol Chem* 273:13375
197. Bellacosa A, Testa JR, Staal SP, Tsichlis PN (1991) A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. *Science* 254:274
198. Ning ZQ, Li J, Arceci RJ (2001) Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. *Blood* 97:3559
199. Blume-Jensen P, Janknecht R, Hunter T (1998) The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. *Curr Biol* 8:779
200. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) [see comments]. *Cell* 87:619
201. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. *Science* 278:687
202. Kane LP, Shapiro VS, Stokoe D, Weiss A (1999) Induction of NF-kappaB by the Akt/PKB kinase. *Curr Biol* 9:601
203. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature* 378:785
204. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. *Nature* 399:601
205. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF,



## References

---

- Papapetropoulos A, Sessa WC (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. *Nature* 399:597
206. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC (1998) Regulation of cell death protease caspase-9 by phosphorylation. *Science* 282:1318
207. Burgering BM, Coffey PJ (1995) Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. *Nature* 376:599
208. Rena G, Guo S, Cichy SC, Unterman TG, Cohen P (1999) Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. *J Biol Chem* 274:17179
209. Tang ED, Nunez G, Barr FG, Guan KL (1999) Negative regulation of the forkhead transcription factor FKHR by Akt. *J Biol Chem* 274:16741
210. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell* 96:857
211. Shiojima I, Walsh K (2002) Role of Akt signaling in vascular homeostasis and angiogenesis. *Circ Res* 90:1243
212. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N (2001) Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. *Genes Dev* 15:1406
213. Kohn AD, Takeuchi F, Roth RA (1996) Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. *J Biol Chem* 271:21920
214. Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH (1997) Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. *J Biol Chem* 272:17269
215. Tanti JF, Grillo S, Gremeaux T, Coffey PJ, Van Obberghen E, Le Marchand-Brustel Y (1997) Potential role of protein kinase B in glucose transporter 4 translocation in adipocytes. *Endocrinology* 138:2005
216. Hajduch E, Alessi DR, Hemmings BA, Hundal HS (1998) Constitutive activation of protein kinase B alpha by membrane targeting promotes glucose and system A amino acid transport, protein synthesis, and inactivation of glycogen synthase kinase 3 in L6 muscle cells. *Diabetes* 47:1006
217. Summers SA, Garza LA, Zhou H, Birnbaum MJ (1998) Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. *Mol Cell Biol* 18:5457
218. Wang Q, Somwar R, Bilan PJ, Liu Z, Jin J, Woodgett JR, Klip A (1999) Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts.



- Mol Cell Biol 19:4008
219. Kang SS, Kwon T, Kwon DY, Do SI (1999) Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. *J Biol Chem* 274:13085
  220. Stein RC, Waterfield MD (2000) PI3-kinase inhibition: a target for drug development? *Mol Med Today* 6:347
  221. Yamaguchi H, Wang HG (2001) The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. *Oncogene* 20:7779
  222. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C (1999) The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. *Genes Dev* 13:382
  223. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV (2001) Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. *Mol Cell Biol* 21:893
  224. Du K, Montminy M (1998) CREB is a regulatory target for the protein kinase Akt/PKB. *J Biol Chem* 273:32377
  225. Anderson MJ, Viars CS, Czekay S, Cavenee WK, Arden KC (1998) Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. *Genomics* 47:187
  226. Davis RJ, Bennicelli JL, Macina RA, Nycum LM, Biegel JA, Barr FG (1995) Structural characterization of the FKHR gene and its rearrangement in alveolar rhabdomyosarcoma. *Hum Mol Genet* 4:2355
  227. Sublett JE, Jeon IS, Shapiro DN (1995) The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. *Oncogene* 11:545
  228. Borkhardt A, Repp R, Haas OA, Leis T, Harbott J, Kreuder J, Hammermann J, Henn T, Lampert F (1997) Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23). *Oncogene* 14:195
  229. Hillion J, Le Coniat M, Jonveaux P, Berger R, Bernard OA (1997) AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily. *Blood* 90:3714
  230. Biggs WH, 3rd, Meisenhelder J, Hunter T, Cavenee WK, Arden KC (1999) Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. *Proc Natl Acad Sci U S A* 96:7421
  231. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM (1999) Direct control of the Forkhead transcription factor AFX by protein kinase B. *Nature* 398:630
  232. Zheng WH, Kar S, Quirion R (2000) Insulin-like growth factor-1-induced phosphorylation of the forkhead family transcription factor FKHL1 is mediated by Akt

## References

---

- kinase in PC12 cells. *J Biol Chem* 275:39152
233. Dijkers PF, Birkenkamp KU, Lam EW, Thomas NS, Lammers JW, Koenderman L, Coffe PJ (2002) FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. *J Cell Biol* 156:531
234. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffe PJ (2000) Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. *Curr Biol* 10:1201
235. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, Coffe PJ (2000) Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). *Mol Cell Biol* 20:9138
236. Kaushansky K (2003) Thrombopoietin: accumulating evidence for an important biological effect on the hematopoietic stem cell. *Ann N Y Acad Sci* 996:39
237. Audet J, Miller CL, Rose-John S, Piret JM, Eaves CJ (2001) Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells. *Proc Natl Acad Sci U S A* 98:1757
238. Mason TM, Lord BI, Hendry JH (1989) The development of spatial distributions of CFU-S and in-vitro CFC in femora of mice of different ages. *Br J Haematol* 73:455
239. Cipolleschi MG, D'Ippolito G, Bernabei PA, Caporale R, Nannini R, Mariani M, Fabbiani M, Rossi-Ferrini P, Olivotto M, Dello Sbarba P (1997) Severe hypoxia enhances the formation of erythroid bursts from human cord blood cells and the maintenance of BFU-E in vitro. *Exp Hematol* 25:1187
240. Cottrell MB, Jackson CW, McDonald TP (1991) Hypoxia increases erythropoiesis and decreases thrombocytopoiesis in mice: a comparison of two mouse strains. *Proc Soc Exp Biol Med* 197:261
241. Danet GH, Pan Y, Luongo JL, Bonnet DA, Simon MC (2003) Expansion of human SCID-repopulating cells under hypoxic conditions. *J Clin Invest* 112:126
242. Dong Z, Nishiyama J, Yi X, Venkatachalam MA, Denton M, Gu S, Li S, Qiang M (2002) Gene promoter of apoptosis inhibitory protein IAP2: identification of enhancer elements and activation by severe hypoxia. *Biochem J* 364:413
243. Beitner-Johnson D, Rust RT, Hsieh TC, Millhorn DE (2001) Hypoxia activates Akt and induces phosphorylation of GSK-3 in PC12 cells. *Cell Signal* 13:23
244. Semenza G (2002) Signal transduction to hypoxia-inducible factor 1. *Biochem Pharmacol* 64:993
245. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O<sub>2</sub> tension.

- Proc Natl Acad Sci U S A 92:5510
246. Huang LE, Gu J, Schau M, Bunn HF (1998) Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. *Proc Natl Acad Sci U S A* 95:7987
247. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L (1999) Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. *J Biol Chem* 274:6519
248. Salceda S, Caro J (1997) Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. *J Biol Chem* 272:22642
249. Sutter CH, Laughner E, Semenza GL (2000) Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. *Proc Natl Acad Sci U S A* 97:4748
250. Harris AL (2002) Hypoxia--a key regulatory factor in tumour growth. *Nat Rev Cancer* 2:38
251. Adelman DM, Maltepe E, Simon MC (2000) HIF-1 is essential for multilineage hematopoiesis in the embryo. *Adv Exp Med Biol* 475:275
252. Adelman DM, Maltepe E, Simon MC (1999) Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. *Genes Dev* 13:2478
253. Scortegagna M, Morris MA, Oktay Y, Bennett M, Garcia JA (2003) The HIF family member EPAS1/HIF-2alpha is required for normal hematopoiesis in mice. *Blood* 102:1634
254. Minet E, Michel G, Mottet D, Raes M, Michiels C (2001) Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation. *Free Radic Biol Med* 31:847
255. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. *Cancer Res* 60:1541
256. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ (1997) Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. *Blood* 90:3322
257. Larrivee B, Lane DR, Pollet I, Olive PL, Humphries RK, Karsan A (2003) Vascular endothelial growth factor receptor-2 induces survival of hematopoietic progenitor cells. *J Biol Chem* 278:22006

## References

---

- 258. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, Hong K, Marsters JC, Ferrara N (2002) VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. *Nature* 417:954
- 259. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. *Mol Cell Biol* 21:3995
- 260. Tang TT, Lasky LA (2003) The forkhead transcription factor FOXO4 induces the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-independent mechanism. *J Biol Chem* 278:30125
- 261. Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, McCormick F, Feng J, Tsichlis P (1998) Akt activation by growth factors is a multiple-step process: the role of the PH domain. *Oncogene* 17:313
- 262. Li CL, Johnson GR (1994) Stem cell factor enhances the survival but not the self-renewal of murine hematopoietic long-term repopulating cells. *Blood* 84:408
- 263. Matsunaga T, Kato T, Miyazaki H, Ogawa M (1998) Thrombopoietin promotes the survival of murine hematopoietic long-term reconstituting cells: comparison with the effects of FLT3/FLK-2 ligand and interleukin-6. *Blood* 92:452
- 264. Langtimm-Sedlak CJ, Schroeder B, Saskowski JL, Carnahan JF, Sieber-Blum M (1996) Multiple actions of stem cell factor in neural crest cell differentiation in vitro. *Dev Biol* 174:345
- 265. Luens KM, Travis MA, Chen BP, Hill BL, Scollay R, Murray LJ (1998) Thrombopoietin, kit ligand, and flk2/flt3 ligand together induce increased numbers of primitive hematopoietic progenitors from human CD34+Thy-1+Lin- cells with preserved ability to engraft SCID-hu bone. *Blood* 91:1206
- 266. Murray LJ, Young JC, Osborne LJ, Luens KM, Scollay R, Hill BL (1999) Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34+ cells and recruit primitive CD34+ Thy-1+ cells into rapid division. *Exp Hematol* 27:1019
- 267. Miller CL, Rebel VI, Helgason CD, Lansdorp PM, Eaves CJ (1997) Impaired steel factor responsiveness differentially affects the detection and long-term maintenance of fetal liver hematopoietic stem cells in vivo. *Blood* 89:1214
- 268. Katayama N, Clark SC, Ogawa M (1993) Growth factor requirement for survival in cell-cycle dormancy of primitive murine lymphohematopoietic progenitors. *Blood* 81:610
- 269. Huss R, Gatsios P, Graeve L, Lange C, Eissner G, Kolb HJ, Thalmeier K, Heinrich PC (2000) Quiescence of CD34-negative haematopoietic stem cells is mediated by downregulation of Cyclin B and no stat activation. *Cytokine* 12:1195

270. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M, Scadden DT (2000) Hematopoietic stem cell quiescence maintained by p21cip1/waf1. *Science* 287:1804
271. Gommerman JL, Berger SA (1998) Protection from apoptosis by steel factor but not interleukin-3 is reversed through blockade of calcium influx. *Blood* 91:1891
272. Yee NS, Paek I, Besmer P (1994) Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: basis for radiosensitivity of white spotting and steel mutant mice. *J Exp Med* 179:1777
273. De Miguel MP, Cheng L, Holland EC, Federspiel MJ, Donovan PJ (2002) Dissection of the c-Kit signaling pathway in mouse primordial germ cells by retroviral-mediated gene transfer. *Proc Natl Acad Sci U S A* 99:10458
274. Uddin S, Kottegoda S, Stigger D, Platanias LC, Wickrema A (2000) Activation of the Akt/FKHRL1 pathway mediates the antiapoptotic effects of erythropoietin in primary human erythroid progenitors. *Biochem Biophys Res Commun* 275:16
275. Kashii Y, Uchida M, Kirito K, Tanaka M, Nishijima K, Toshima M, Ando T, Koizumi K, Endoh T, Sawada K, Momoi M, Miura Y, Ozawa K, Komatsu N (2000) A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. *Blood* 96:941
276. G-Amlak M, Uddin S, Mahmud D, Damacela I, Lavelle D, Ahmed M, van Besien K, Wickrema A (2002) Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. *Biochem Biophys Res Commun* 297:760
277. Tanaka M, Kirito K, Kashii Y, Uchida M, Watanabe T, Endo H, Endoh T, Sawada K, Ozawa K, Komatsu N (2001) Forkhead family transcription factor FKHRL1 is expressed in human megakaryocytes. Regulation of cell cycling as a downstream molecule of thrombopoietin signaling. *J Biol Chem* 276:15082
278. Mahmud DL, M GA, Deb DK, Platanias LC, Uddin S, Wickrema A (2002) Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. *Oncogene* 21:1556
279. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. *Cancer Res* 62:3387
280. Plas DR, Talapatra S, Edinger AL, Rathmell JC, Thompson CB (2001) Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. *J Biol Chem* 276:12041
281. Bilton RL, Booker GW (2003) The subtle side to hypoxia inducible factor (HIF $\alpha$ ) regulation. *Eur J Biochem* 270:791

## *References*

---

- 282. Semenza GL, Roth PH, Fang HM, Wang GL (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. *J Biol Chem* 269:23757
- 283. Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. *J Biol Chem* 277:23111
- 284. Stryer L (1988) *Biochemistry*. New York: New York
- 285. Blazsek I, Comisso M, Farabos C, Misset JL (1991) Roles for the heliodynamic hormones, all trans retinoic acid and 1 alpha, 25-dihydroxyvitamin D3, in control of the hematopoietic cell cycle. *Biomed Pharmacother* 45:157
- 286. Mogi M, Yang J, Lambert JF, Colvin GA, Shiojima I, Skurk C, Summer R, Fine A, Quesenberry PJ, Walsh K (2003) Akt-signaling regulates side-population cell phenotype via Bcrp1 translocation. *J Biol Chem*
- 287. Penso J, Beitner R (2003) Lithium detaches hexokinase from mitochondria and inhibits proliferation of B16 melanoma cells. *Mol Genet Metab* 78:74